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Abstract
Pancreatic ductal adenocarcinoma has one of the most unfavourable prognoses and 
survival patterns. Pancreatic intraepithelial ductal neoplasias (PanlNs) 1-3 are mi­
croscopic precursors which display genetic and epigenetic changes leading to adeno­
carcinoma. We investigated the chromosomal numeric changes for chromosomes 1, 
6, 9 and 18 using fluorescence in situ hybridization in the progressing intraepithelial 
neoplasias and the corresponding tumours. We also assessed the protein levels for mi­
totic checkpoint proteins Mad2 and BubRl using immunohistochemistry and applied 
correlation models to derive potential significant correlations to chromosome numeric 
anomalies and clinicopathological parameters. The results revealed that, for the chro­
mosomes included in the study, the average numeric anomalies (aneuploidy) increases 
with the advancing histological stage. Moreover, the extra copy anomalies (amplifi­
cations) were significantly higher in the final precancerous stage (PanIN 3) and/or the 
cancer stage (p-value<0.05). The protein levels for Mad2 and BubRl did not show a 
direct correlation to the aneuploidy levels but that could be due to the diversity of the 
individual tumour makeup and the limited specimens included in the analysis. In the 
current trend towards personalized genetic therapy for aggressive tumours, the aneu­
ploidy levels and the mitotic checkpoint protein levels could potentially be incorpo­
rated in a panel of biomarkers used to predict prognoses and survival patterns.
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Chapter 1
General Introduction
1.1 Pancreatic ductal adenocarcinoma
1.1.1 Epidemiology
Pancreatic cancer is currently the 5th most common cause of cancer death and repre­
sents 5% of all deaths from cancer in the UK (2011), with equal distribution between 
males and females. 8320 deaths from pancreatic cancer were recorded in the UK in 
2011, with a male to female ratio of 1:1. The crude mortality rate associated with 
pancreatic cancer is the same for the male and female population (13 cancer deaths 
per every 100000 males/females). Age-specific mortality rates increase significantly 
for the >55 age group (11 cancer deaths per every 100000 females and 16 cancer 
deaths per every 100000 males), with the highest rates in the >85 age group (94 can­
cer deaths per every 100 000 females and 110 cancer deaths per every 100 000 males). 
The male to female ratio varies with the age group and the widest difference in age- 
specific mortality is for the 45-49 age group (15:10). Worldwide, pancreatic cancer is 
the 1th most common cause of cancer death, with more than 330 000 deaths in 2012 
(4% of total) (Cancer Research UK 2014). On average, 4.1 new cases are diagnosed 
per year per 100 000 people worldwide (Ferlay J et al., 2010). The 5-year survival rate 
is less than 4%. This is due to the failure to diagnose early curable disease, a pattern 
of aggressive dissemination and resistance to available systemic therapeutic regimens 
(Carpelan-Holmstrom M et al., 2005, Benson AB, 2007).
The main known risk factors are tobacco smoking, chronic pancreatitis, late-onset 
diabetes mellitus and increased body mass index (Ghaneh P, 2008). 10% of cases are 
associated with an inherited predisposition based on familial clustering (Hezel A et al., 
2006).
Several genetic syndromes are associated with an increased risk for pancreatic can­
cer, which include:
• Hereditary breast and ovarian cancer syndrome, associated with mutations in the
1
BRCA2 gene.
• Familial melanoma, associated with mutations in the pl6/CDKN2A gene.
• Familial pancreatitis, associated with mutations in the PRSS1 gene.
• Hereditary non-polyposis colorectal cancer (HNPCC), commonly associated with 
mutations in the MLH1 or MSH2 genes, but also in MLH3, MSH6, TGBR2, 
PMS1 and PMS2 genes.
• Peutz-Jeghers syndrome, associated with mutations in the STK11 gene.
• Von Hippel-Lindau syndrome, associated with mutations in the VHL gene (Wolf­
gang CL et al., 2013).
There is no population screening programme for pancreatic cancer but surveillance 
is recommended for patients with a strong family history, certain genetic syndromes 
(Peutz-Jeughers syndrome, familial atypical multiple mole melanoma, ataxia telang­
iectasia syndrome) and hereditary pancreatitis (Brand RE et al., 2007).
1.1.2 Anatomy and physiology
The pancreas lies posteriorly to the stomach on the posterior abdominal wall. It is 
divided in head, neck, body and tail. It lies obliquely, with the head towards the right 
side, in contact with the duodenum and the tail towards the spleen. The main pancreatic 
duct runs longitudinally in the organ and drains the pancreatic juice into the duodenum 
through the major duodenal papilla (ampula of Vater) alongside the common bile duct 
which drains the bile from the liver and the gallbladder. When the main pancreatic duct 
is accompanied by an accessory pancreatic duct, the latter drains into the duodenum 
through the minor duodenal papilla (Fig. 1.1). (Beger HG et al. ed, 2008:52).
The pancreas has an endocrine and an exocrine function. The endocrine tissue is 
represented by endocrine cells grouped in the islets of Langerhans. Specialised cells 
(a:, /3, 7 and PP) express insulin, glucagon, somatostatin and pancreatic polypeptide 
respectively, which are transported via the blood flow.
The exocrine tissue is represented by the acinar exocrine cells grouped in acini. 
They express digestive enzymes like trypsin and lipase which are transported via a 
ductal system leading to the main pancreatic duct draining into the duodenum. The 
ducts are lined with epithelial cells. Connective tissue forms a supportive matrix for 
the ducts as well as the blood vessels, lymphatic vessels and nerves which provide 
functional support (Dockman DE, 2008:50).
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Figure 1.1: Anatomy of the pancreas, illustrating the position of the pancreas related 
to the stomach, spleen, liver, gallbladder and duodenum. The main pancreatic duct 
drains into the duodenum through the major duodenal papilla alongside the common 
bile duct. The accessory pancreatic duct drains into the duodenum through the minor 
duodenal papilla (The pancreas and adjacent anatomy, 2014).
1.1.3 Histopathology
Over 85% of pancreatic tumours are ductal adenocarcinomas. Other types of tumours 
include: acinar cell carcinoma, acinar cell cystadenocarcinoma, fibrosarcoma, pancre- 
atoblastoma (Williams NA ed, 2013:1129).
The carcinogenesis process in ductal adenocarcinoma is initiated in the ductal cells 
and extends to the rest of the tissue as the process advances (Hruban RH et al., 2004). 
The tissue architecture in such cancer specimens appears distorted compared to normal 
specimens (Fig. 1.2).
Pancreatic ductal adenocarcinoma progression leads to local invasion to adjacent 
structures like regional lymph nodes, gastro-intestinal blood vessels, duodenum and 
stomach, and to distant metastases most commonly to lung, brain and peritoneum 
(Wolfgang CL et al., 2013).
3
(a) Norm al pancreas with islet o f  Lager- (b) Pancreatic ductal adenocarcinom a with 
hans (endocrine structure) and acini (ex- distorted tissue architecture; interlobular 
ocrine com ponent) (arrows). ducts and blood vessel (arrows).
Figure 1.2: Photomicrographs x 10 of HE sections of normal pancreatic tissue and 
pancreatic ductal adenocarcinoma, respectively.
1.1.4 Premalignant lesions
The premalignant lesions in PDAC are: pancreatic intraepithelial neoplasia (PanIN), 
mucinous cystic neoplasm (MCN), intraductal mucinous papillary neoplasm (IPMN) 
and intraductal tubulopapillary neoplasm (ITPN) (de Wilde RF et al., 2012, Brosens 
LAA et al., 2013, Distler M et al., 2014). Even though adenocarcinomas may be a 
result of any of the precursor lesions, the ones associated with PanlNs are far more 
common (13 to 100-fold) in pancreatectomy specimens (Winter JM, 2006). One of the 
reasons for this is the higher frequency of early diagnosis for non-invasive IPMNs and 
MCNs (Gaujoux S, 2011).
IPMNs are macroscopically visible mucin-producing cystic tumours located in the 
main pancreatic duct or one of its branches (Shi C et al., 2012). The associated symp­
toms include abdominal or back pain, nausea, vomiting, or recurrent episodes of pan­
creatitis and are caused by a dilated main pancreatic duct due to an increase in the 
production of mucin (Ghaneh P et al., 2006). IPMNs can be associated with invasive 
PDAC and in such cases the 5-year survival is 30-60% compared to 90-100% for the 
cases without invasive PDAC (Crippa S et al., 2010).
MCNs are macroscopically visible cystic tumours, most frequently located in the 
body and tail of pancreas and which do not communicate with the pancreatic ductal 
system. They can cause non-specific symptoms like abdominal discomfort (Zamboni 
G et al., 2010). When associated with invasive PDAC, the 5-year survival rate is 50- 
60% compared to 90-100% when not associated with invasive PDAC (de Wilde RF et 
al., 2012).
ITPNs are rare macroscopically large (average 6 cm diameter) solid nodular tu­
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mours found in the pancreatic duct. In contrast to the cystic precursors, there is no 
overt mucin producing component (Yamaguchi H et al., 2009). About 40% cases can 
be associated with invasive PDAC. The 5-year survival is likely more than 30% but not 
enough data is currently available to differentiate between the cases with / respectively 
without invasive PDAC (Adsay NV et al., 2010).
IPMNs, MCNs and ITPNs are managed according to the "Sendai" criteria which 
are based on size, symptoms and evidence of associated malignant changes (Tanaka M 
et al., 2012).
PanlNs are microscopic intraductal lesions that include several different stages: 
PanIN 1 A, PanIN IB, PanIN 2 and PanIN3.
The prevalence of PanlNs increases with age. PanIN 2 is three times more prevalent 
in pancreatic tissue with associated PDAC while PanIN 3 is only found associated with 
PDAC. PanlNs are more common in pancreatic tissue with PDAC (82%) than with 
pancreatitis (60%) or normal tissue (16%). PanlNs 1 and 2 are considered low risk 
lesions for the development of PDAC and they can be seen in normal pancreatic tissue 
as well as associated with non-malignant lesions. PanlNs 3 can be considered fully 
developed neoplastic lesions and they display multiple genetic similarities to invasive 
PDAC (de Wilde RF et al., 2012).
PanlNs are asymptomatic and, at present, cannot be detected by imaging tech­
niques, including endoscopic ultrasound (Distler M et al., 2014). They are most fre­
quently located in the head of the pancreas compared to the body and tail. They mea­
sure less than 5 mm in size and arise in the smaller pancreatic ducts. Histologically, 
PanlNs are lined by columnar mucinous epithelium instead of the normal cuboidal 
pancreatic duct epithelium (Hruban RH et al., 2004). PanIN 1A have a flat epithe­
lial structure with the nuclei basally aligned and supranuclear mucin. PanIN IB have 
a papillary structure, while PanIN 2 display more complexity with pseudostratifica­
tion, nuclear hyperchromasia and loss of nuclear polarity. PanIN 3 are characterized 
by a papillary structure, with cribriform growth. They show significant atypia, with 
complete loss of nuclear polarity, nuclear hyperchromasia and atypical mitotic figures 
(Hruban RH et al. 2004, de Wilde RF et al., 2012).
A step wise progression model for the carcinogenesis process has been suggested 
based on research into the natural history of PanlNs (Fig. 1.3) (Ottenhof NA et al., 
2011).
It was noted that some of the early genetic events occur at the PanIN 1 stage and 
include telomere shortening and the activation of the K-ras oncogene. K-ras mutations 
can initiate PanIN development and they were identified in >90% of both low - and 
high - grade PanIN lesions. The K-ras mutant clone expands during PanIN progres­
sion (Kanda M et al., 2012). Other significant events occur at PanIN 2 and PanIN 
3 stages, like the inactivation of tumour supressor genes p !6 and p53, respectively
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Figure 1.3: Progression model for pancreatic intraepithelial neoplasia (PanIN). The 
progressive histological changes are shown in the top row photomicrographs 
(hematoxylin and eosin (HE) staining, x40). The stepwise accumulation of genetic 
mutations is illustrated below the pictures (Ottenhof NA et. al., 2011)
(Hruban HR et al., 2000). p i 6 mutations were found in 11% of early PanIN lesions 
and more often in lesions without K-ras mutation (Kanda M et al., 2012). Loss of 
p 16 protein expression was shown to increase with PanIN grade (Wilentz RE et al., 
1998). Inactivation of p53 is a late event and is found in 30-50% cases with PanIN 3 
and invasive PDAC. Inactivation of SMAD4 gene is found in 30% PanIN 3 lesions and 
50% cancer cases (Hruban RH et al., 2000). Epigenetic inactivation of tumour supres- 
sor genes by hypermethylation occurs early and increases with PanIN grade (Sato M 
et al., 2008). Overexpression of oncogenes involved in EGFR, Notch and Hedgehog 
signaling occurs in PanlNs associated with invasive PDAC (Miyamoto Y et al., 2003). 
Also, PanIN lesions display aberrant expression of many microRNAs, which may be 
used as diagnostic markers (Yu J et al., 2012).
Research studies investigating specimens of pancreatic tissue with chronic pan­
creatitis isolated premalignant lesions (PanIN 1-3) and demonstrated similar genetic 
changes seen in the PanlNs from cancer specimens: p53 protein overexpression and 
loss of expression for p 16 and DPC4 protein in PanIN 3, increasing aneuploidy from 
PanIN 1A to PanIN 3 (Baumgart M et al., 2010).
It was calculated using a computerised model that the time interval between the 
initiating tumour cell and the parental clone could be 10 years and that 5 more years 
could lead to fully metastatic disease (Yachida S et al., 2010).
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1.1.5 Genetic pathways
Current knowledge based on extensive experimental and epidemiological data indi­
cates that pancreatic cancer is a genetic disease. PDAC is characterized by the accu­
mulation of a high number of gene deletions, mutations and amplifications.
The genes most commonly involved in pancreatic cancer are: KRAS2, pl6/CDKN2A, 
TP53 and SMAD4/DPC4.
The KRAS2 oncogene is activated in virtually all cases of pancreatic cancer and 
is the most common genetic abnormality seen in this type of cancer (Almoguera C et 
al., 1988). Ras is a membrane-bound GTP-binding protein with a role in the growth 
factor-mediated signaling pathways. KRAS mutations lead to an activated form of 
Ras, locked in the GTP-bound state and able to stimulate a variety of downstream 
signaling pathways (Malumbres M et al., 2003). Mutations of this gene occur early 
in the progression model, namely in the PanIN 1A stage (Moskaluk CA et al., 1997). 
KRAS mutations can also be seen in nearly 25% of cases with chronic pancreatitis and 
even in healthy elderly population (Guerra et al., 2007).
The inactivation of the CDKN2A (p i6) tumour suppressor gene is seen in up to 
90% of all pancreatic cancers (Caldas C et al., 1994) and it can occur through homozy­
gous deletion, mutation with loss of the second allele or epigenetic silencing of the 
locus on chromosome 9 (Schutte M et al., 1997). The p l6 tumour suppressor pathway 
plays a vital role in cell proliferation by regulating entry into the S-phase of cell cycle 
(Sherr CJ, 2004, Liu H et al., 2004). p l6 can be inactivated as early as the PanIN 2 
stage (Moskaluk CA et al., 1997).
The TP53 gene is inactivated in a large proportion of pancreatic cancers (50-75%) 
(Redston MS et al., 1994), usually by mutation with loss of the second allele (Vogel- 
stein B et al., 2000). The TP53 protein becomes activated and increases as a result of 
the oncogenic mutations, regulating a transcription response towards cell-cycle arrest 
or apoptosis (Sherr CJ, 2004). TP53 mutations are seen starting in the PanIN 3 lesions 
(DiGiuseppe JA et al., 1995).
The SMAD4 gene is inactivated in approximately 55% of the pancreatic cancers by 
homozygous deletion or mutation with loss of the second allele (Hahn SA et al., 1996). 
The MADH4 locus on chromosome 18 (18q21.1) encodes SMAD4 and it undergoes 
loss of heterozygosity in 90% of tumours (Rane SG et al., 2006). The loss of SMAD4 
has significant effects on tumour microenvironment and tumour invasion (Schwarte- 
Waldhoff I et al., 2000, Duda DG et al., 2003) through its role in signal transmission 
for the TGF-/3 superfamily of cytokines (Bierie B et al., 2006). The inactivation can 
occur from the PanIN 3 stage (Wilentz RE et al., 2000).
Two of the most important pathways involved in pancreatic carcinogenesis are the 
Notch and the Hedgehog pathways.
The Notch pathway is instrumental in the processes of apoptosis, differentiation
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and proliferation in pancreatic cancer initiation and invasion (Leach SD et al., 2005, 
Lomberk G et al., 2005). The Notch pathway also promotes tumour vascularisation 
(Rehman RO et al., 2006) which prompts advanced research into possible drug targets. 
The genes involved in this pathway are upregulated in the precursor lesions as well as 
in the invasive tumour (Miyamoto M et al., 2003).
The Hedgehog signaling pathway includes three different members: sonic, desert 
and Indian hedgehog, which coordinate the development of the gastrointestinal tract in 
association with other ligands (Thayer SP et al., 2003, Prasad NB et al., 2005, Kayed H 
et al., 2006). The Hedgehog signaling pathway mainly coordinates the development of 
the gastrointestinal tract. Upregulation of the genes involved in the Hedgehog pathway 
is initiated in the early premalignant stages (Prasad N et al., 2005). The Sonic hedge­
hog is believed to be involved in the development of the pancreatic cancer stem cells 
which are presumed potential precursor cells for pancreatic cancer. One study iden­
tified a specific phenotype (CD44 CD24 ESA) from primary pancreatic cancer cells 
that has a 100-fold increased malignant potential but detailed characterization of the 
molecular signature and progression pathway is still in research (Li C et al., 2007).
A variety of other genes are involved but with a lower frequency. The gene sets 
have been linked to 12 core signaling pathways and processes relevant to pancreatic 
carcinogenesis (Fig. 1.4). Only one gene from a pathway is usually involved in a 
specific carcinoma specimen while a wide range of genes is connected to different 
specimens (Iacobuzio-Donahue CA, 2012).
Core signalling pathways 
in pancreatic cancer
Figure 1.4: The main signaling pathways involved in pancreatic cancer 
(Iacobuzio-Donahue CA, 2012)
Each of the premalignant stages in the PanIN progression is associated with other 
less frequent genetic changes that contribute to the carcinogenesis process (Table 1.1) 
(Ghaneh P et al., 2008).
Table 1.1: Genetic alterations in the pre-malignant stages PanIN 1, PanIN 2 and
PanIN 3 (Ghaneh P et al., 2008)
PanIN 1 PanIN 2 PanIN 3
K-ras Cyclin D1 p53
Telomere shortening Cyclo-oxygenase 2 
(COX 2)
SMAD4
p21 (WAF1/CIP1) Hesl (Hair and enhancer 
of split 1)
BRCA2
Human epidermal growth 
factor receptor 2 
(Her2 / neu)
Notch 1 S100P
Mucin 1 (MUC1) Pepsinogen C SHH
MUC6 Kruppel-like factor 4 
(KLF4)
SialyT (mucin-associate 
carbohydrate antigen)
Trefoil factor 1 (TFF1) HOXA5 Maspin
p l6 (INK4a) GATA5 MUC4
S100A11 Gastrin Tumour suppressor 
in-lung cancer-1 
(TSLC 1)
MUC5AC Villin 1 Familial adenomatous 
polyposis (FAP)
S100A6 Villin 2
Cellular retinoic acid 
binding protein 4 
(CRABP 4)
Despite advances in studying cancer tissue the survival rates have not improved 
therefore major emphasis is currently placed on studying the premalignant stage in 
view of identifying and validating potential biomarkers for early detection. Currently 
there is no validated diagnostic method able to detect PanlNs but the ongoing progress
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in state-of-the-art radiology remains promising. The PanlNs described by research 
studies come from surgical specimens resected for benign or malignant conditions or 
from mouse models. Genetically engineered mouse models, where one or more genes 
(KRAS, SMAD4) known to be involved in pancreatic carcinogenesis have been inacti­
vated, can display the full route to cancer and metastasis as seen in humans (Bardessy 
N et al., 2006, Hingorani SR et al., 2005, Skoulidis F et al., 2010).
Increasing evidence from work carried out on pancreatic cancer specimens ob­
tained at autopsy on patients with end stage disease suggests that a personalized ap­
proach to therapy could lead to improved outcome. For example, the status of the 
DPC4 gene in the tissue could direct treatment: patients with borderline resectable 
tumours and loss of DPC4 expression may indicate a high risk for distant spread and 
therefore be treated with systemic rather than locoregional therapy; if the DPC4 gene 
is retained, the patient could have adjuvant chemoradiotherapy. This is early stage 
retrospective data but there is an outstanding potential in this approach as genetic and 
targeted therapy advance (Iacobuzio-Donahue CA, 2012).
1.1.6 Biomarkers
The definition of a tumour marker is “a naturally occurring molecule that is measured 
in serum or plasma, or other body fluids or in tissue extracts or paraffin-embedded 
tissue to identify the presence of cancer, to assess patient prognosis, or to monitor a 
patient’s response to therapy with the overall goal of improving the clinical manage­
ment of the patient” (Fleisher M et al., 2002).
Biomarkers are classified in:
1. pre-disposition biomarkers, designed to identify at risk cases
2. screening biomarkers, used for early detection in general or at risk populations;
3. diagnostic biomarkers, for defining the tumour type, stage and grade;
4. prognostic biomarkers, used to identify the likely clinical disease course;
5. predictive biomarkers, designed to illustrate patient likelihood to benefit from 
individual therapies;
6. pharmacological biomarkers, used to monitor drug effects;
7. surrogate response biomarkers, for early prediction of ultimate clinical efficiency 
(Cancer Research UK, 2014).
There are no established pre-disposition or screening biomarkers in pancreatic can­
cer.
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The only marker used in clinical practice for pancreatic cancer is CA 19-9 which 
has 90% specificity and 80% sensitivity (Steinberg H, 1990). However, CA 19-9 is a 
prognostic biomarker only relevant in monitoring for response to adjuvant therapy and 
for recurrence. Increased values can be seen in obstructive jaundice of non-malignant 
origin, chronic pancreatitis, cholangitis, cirrhosis and other gastrointestinal cancers 
therefore its independent diagnostic power is limited (Duffy MJ et al., 2010). Fur­
thermore, CA 19-9, a syalilated antigen of the MUC1 protein, cannot be detected 
in patients with certain blood types who cannot express the antigen recognized by 
it (Steinberg H, 1990).
A wide range of potential diagnostic and predictive biomarkers relevant to pancre­
atic cancer are under investigation but so far they failed to be translated into clinical 
use (Buxbaum JL et al., 2010).
A systematic review on immunohistochemistry-based tissue biomarkers relevant 
in pancreatic cancer found a limited panel of promising markers for the prediction of 
overall survival: BAX (HR=0.31,95% Cl: 0.71-0.56), Bcl-2 (HR=0.41, 95% Cl: 0.27- 
0.63), survivin (HR=0.46, 95% Cl: 0.29-0.73), Ki-67 (HR=2.42, 95% Cl: 1.8-3.14), 
COX-2 (HR=1.39, 95% Cl: 1.13-1.71), E-cadherin (HR=1.80, 95% Cl: 1.33-2.42) and 
S100A2 calcium-binding protein (HR=3.23, 95% Cl: 1.58-6.62) (Jamieson NB et al., 
2011).
CA242, CAM 17.1 and TPS are candidate serum protein diagnostic markers under 
evaluation. MIC-1, osteopontin and TIMP-1 are candidate serum protein diagnostic 
markers in the research phase (Goggins M, 2010).
Pancreatic juice analysis could yield a panel of markers relevant in early detection. 
Thus, mutant K-ras, mutant p53, methylated DNA and mithocondrial DNA mutations 
are under evaluation as part of pancreatic juice analysis (Goggins M, 2010).
In other types of cancer molecular markers are already used in tailoring therapy: 
Kras sequencing (Van Cutsem E et al., 2009) and microsatellite instability (Jover R et 
al., 2009, Ribic CM et al., 2003) in colorectal cancer; hormone receptor status (Collab 
group, 1998) and Her2 expression (Perez EA et al., 2011) in breast cancer and similarly 
for melanoma (Chapman PB et al., 2011), lung cancer (Shedden K et al., 2008) and 
prostate cancer (Cheville JC et al., 2008).
1.1.7 Diagnosis
In the sections for diagnosis, staging and standard therapy the term pancreatic cancer 
refers to pancreatic ductal adenocarcinoma only, unless stated otherwise. Most fre­
quently, pancreatic cancer is asymptomatic until late stage. The symptoms are usually 
non-specific like anorexia, weight loss, upper abdominal discomfort. Painless jaundice 
is associated with pancreatic cancer and is the symptom which draws medical atten­
tion. The first line of investigations includes blood tests and abdominal ultrasound
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scan. If there is a suspicion of pancreatic cancer, the next test is a contrast-enhanced 
helical computerised tomography (CT) scan specific for the pancreas which is used 
for diagnosis and staging. Also, endoscopic ultrasound (EUS) is used to characterize 
the tumour and its extent and, potentially, to obtain biopsy. If surgery is appropriate 
based on the information obtained from CT and EUS and after assessing patient fit­
ness, surgical resection is planned without delay. Another potential investigation is 
endoscopic retrograde colangiopancreatography (ERCP) which can be accompanied 
by biopsy and / or insertion of a stent to relieve the jaundice. Biopsies are impor­
tant especially in palliative cases, to help tailor palliative therapy. For the cases which 
undergo radical surgery biopsy is not mandatory. Only in the cases where imaging 
of a pancreatic lesion is ambigous biopsy is peformed via EUS (Seufferlein T et al., 
2012). Magnetic resonance cholangiopancreatography (MRCP) is non-invasive and 
can be used to gather information about the tumour and the adjacent bile ducts but can­
not be used for biopsy. Percutaneous transhepatic cholangiography (PTC) is used for 
stent placement in the cases where ERCP is not feasible (Williams NA ed, 2013:1128- 
29). Positron emission tomography - computer tomography (PET-CT) is indicated for 
staging in potentially operable cases where other imaging is equivocal for metastatic 
disease and a positive PET-CT would lead to a decision not to operate (The Royal Col­
lege of Physicians and Royal College of Radiologists, 2013). Tumour markers like CA 
19-9 have limited diagnostic value. CA 19-9 is not specific for pancreatic cancer and 
can increase in non-malignant disease (Seufferlein T et al., 2012).
1.1.8 Staging
The staging system in pancreatic cancer is provided by the TNM staging system from 
The American Joint Committee on Cancer (AJCC) and The Union for International 
Cancer Control (UICC). The TNM staging system is determined by details on the 
primary tumour, regional lymph nodes and distant metastases (Seufferlein T et al., 
2012) (Table 1.2).
Based on the TNM system, pancreatic cancer is divided into stage 0, IA, IB, ILA, 
IIB, III and IV (Seufferlein T et al., 2012) (Table 1.3).
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Table 1.2: TNM classification for pancreatic cancer (Seufferlein T et al., 2012)
Primary Tumour
Tx Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour limited to the pancreas, ^2cm in greatest dimension
T2 Tumour limited to the pancreas, >2cm in greatest dimension
T3 Tumour extends beyond the pancreas but without involvement of the celiac
axis or the superior mesenteric artery
T4 Tumour involves the celiac axis or the superior mesenteric artery (unresectable
primary tumour)
Regional lymph nodes
Nx Regional lymph nodes cannot be assessed
NO No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastases
MO No distant metastasis 
M l Distant metastasis
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Table 1.3: Stage grouping of pancreatic cancer (Seufferlein T et al., 2012)
Stage T N M
0 Tis NO M0
IA T1 NO M0
IB T2 NO M0
IIA T3 NO M0
IIB T1 NO M0
IIB T2 N1 M0
IIB T3 N1 M0
III T4 Any N M0
IV Any T Any N Ml
1.1.9 Standard therapy
The therapy in pancreatic cancer is guided by the staging system (Seufferlein T et al., 
2012, Wolfgang CL, 2013). Most patients (50-60%) present with metastatic disease. 
25-30% patients present with locally invasive/unresectable tumours. 15-20% patients 
present with resectable/borderline resectable tumours (Mauro LA et al., 2014). The 
only curable therapy is radical surgery. This is suitable for patients with stage I disease 
and some with stage II. The standard surgical intervention for tumours of the pancre­
atic head is partial pancreato-duodenectomy. Distal pancreatectomy is performed for 
tumours located in the body or the tail of the pancreas. In some cases, total pancrea­
tectomy is required (Seufferlein T et al., 2012). The resectability/iresectability criteria 
are governed by The National Comprehensive Cancer Network (NCCN) Guidelines for 
pancreatic adenocarcinoma and are based on the extent of vascular invasion (NCCN, 
2011). A raised level of CA 19-9 post resection, a positive circumferential resection 
margin and a lymph node ratio (LNR) >0.2 (number of positive lymph nodes/total 
number of lymph nodes excised) are negative prognostic factors (Riediger H et al., 
2009). Adjuvant chemotherapy is standard and uses gemcitabine or 5-Fluorouracil 
for a period of 6 months (Neoptolemos JP et al., 2010). Adjuvant chemoradiation is
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controversial. Neoadjuvant chemotherapy, radiotherapy or chemoradiation is used as 
part of clinical trials in resectable cases or in selected cases with borderline resectable 
tumours to downsize the tumour prior to resection. If the tumour is not resectable, 
the aim is to prolong survival by controlling local symptoms and metastatic growth. 
The standard therapy for stages III and IV is chemotherapy alongside symptom con­
trol. Regimens with gemcitabine or FOLFIRINOX (5-Fluorouracil, irinotecan and 
oxaliplatin) are used in this setting. A combined regimen of gemcitabine and erlotinib 
(epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor) can be used in 
selected cases. Other combinations of chemotherapy agents have not showed any sur­
vival benefits. Palliative therapy includes symptom control (pain, nausea) as well as 
stenting in cases with jaundice or duodenal obstruction (Seufferlein T et al., 2012).
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1.2 Aneuploidy
Chromosomal instability (CIN) is defined as an increased rate of chromosome misseg- 
regation in mitosis. The main mechanisms leading to chromosomal instability include 
an underactive or overactive mitotic spindle assembly checkpoint, defects of cohe­
sion between sister chromatids, increased microtubule-kinetochore attachments or the 
presence of extra centrosomes. CIN can manifest itself as gains or losses of whole 
chromosomes (aneuploidy) or gross chromosomal rearrangements.
Aneuploidy is a chromosomal abnormality resulting from either an excess or deficit 
of a chromosome or several chromosomes so that the chromosome number is not an 
exact multiple of the typical haploid set (23).
Stable aneuploidy can occur without chromosomal instability (e.g. Down syndrome- 
trisomy 21) and it is antiproliferative but the aneuploidy seen in cancers is frequently 
caused by CIN. It is usually seen early in carcinogenesis and is associated with a poor 
prognosis (Yuen K et al., 2010).
The cell cycle is divided into interphase and mitosis. The interphase has 3 dis­
tinct stages: G1 (Gap Stage 1), S (Synthesis Stage) and G2 (Gap Stage 2). Mitosis is 
organised in 4 steps: prophase, metaphase, anaphase and telophase. The mitotic cell 
division is designed to ensure proper chromosome segregation through the coordinated 
activities of the cyclin-dependent kinases and spindle assembly checkpoint (SAC).
In G1 there is an increase in protein synthesis so that the cell doubles in size, thus 
the daughter cells have the same function as the original cell. During the S phase the 
DNA is replicated by semi-conservative replication, producing two identical copies 
of each chromosome. The chromosomes get wrapped around proteins called histones 
and together they represent the chromatin. After the DNA replication, two identical 
chromosomes named sister chromatids are held together at a point named centromere. 
The DNA replication is governed by mechanisms that ensure exact copying in order to 
avoid mutations. During G2 there is further cell growth and rapid protein synthesis in 
preparation for mitosis.
During prophase the chromosomes become short and thick and can be visualised 
with a light microscope. The organelle called centriole divides in two and starts to form 
protein threads named spindle (microtubule) fibres. These attach to the centromeres on 
the sister chromatids. In prometaphase the nuclear envelope disappears and the sister 
chromatids individualize along the chromosome arms. In metaphase the chromosomes 
align themselves towards the centre of the cell (equatorial plate of the spindle), held 
by the spindle fibres. During anaphase, the spindle fibres contract separating the sister 
chromatides at the centromere and pulling them towards the opposite poles of the cell. 
In telophase the spindle fibres break down and a nuclear envelope forms around the two 
sets of sister chromatids at the poles of the cell. The cell divides into two (cytokinesis) 
generating two identical daughter cells.
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The SAC acts in prometaphase and its role is to control the timing of anaphase. 
It delays sister chromatids separation until all the chromosomes are attached to the 
spindle (bipolar attachment). It is formed by the products of the MAD (mitotic arrest 
deficient) and BUB (budding uninhibited by benzimidazole) genes, of the Mpsl and 
Aurora B/lpll kinases and additional accessory factors. The main proteins of the spin­
dle assembly checkpoint are: Madl, Mad2, Mad3, Bubl, Bub3, Mpsl and Cdc20. The 
depletion of Mad2 and BubRl proteins leads to a premature anaphase with misaligned 
chromosomes (Silk AD et al., 2013, Lampson MA et al., 2004). The depletion of other 
SAC proteins including Madl, Bubl and Bub3 produces a premature exit from mitosis 
for the cells whose chromosomes are not properly aligned (Varetti G et al., 2008).
Several mechanisms of chromosomal instability have been identified in aneuploid 
human tumour cells: cohesion defects, SAC defects, supernumerary centrosomes, de­
fects in kinetochore-microtubule attachment dynamics and defects in cell cycle regu­
lation (Thompson S et al., 2010).
Aneuploid cells usually occur in most normal tissues due to errors in cell division 
but do not proliferate to produce abnormal clones (Sandberg AA et al., 1961). How­
ever, increased aneuploidy in tumour cells gives a poor prognosis through accelerated 
tumour progression and metastatic potential.
Aneuploidy could represent a biomarker of real value for the personalized approach 
to therapy in pancreatic cancer when correlated with relevant proteomics (i.e. CA19- 
9, CEA), transcriptomics (i.e. microRNA), metabolomics (i.e. glucose, creatine) and 
other genomics (i.e. mutant KRAS, p i6, TP53).
The aberrations seen in pancreatic cancer involve gains or losses of whole-arm 
chromosomes as well as subchromosomal alterations. A wide panel of chromosomes 
are involved as demonstrated by multiple studies using different methods to investi­
gate the genome for pancreatic cancer. Comparative genome hybridization (CGH), 
karyotype analysis and loss of heterozygosity (LOH) studies indicated that frequent 
gains are found in 3q, 5p, 7p, 8q, llq , 12p, 17q and 20q and frequent losses in 3p, 
4q, 6q, 8p, 9p, lOq, 12q, 13q, 17p, 18q, 21q and 22q (Hahn SA et al., 1995, Seymour 
AB et al., 1994, Fuji H et al., 1997, Mahlmaki EH et al., 1997, Sugio K et al., 1997). 
Correlations between the chromosomal anomalies and tumour dissemination proved 
that lymph node metastasis and vascular invasion is related to the genetic signature of 
the specimen (Aguirre AJ et al., 2004). Genome-wide array CGH on pancreatic ductal 
adenocarcinoma specimens revealed losses and gains in multiple different loci, most 
frequently located on lp, llq , 17p, lOq, 8p, 18q, 22q, 6q, 9p, 14q and 17q for losses 
and 7q, 12p, lp, 8q, 12q and 14 q for gains (Loukopoulos P et al., 2007). This illus­
trates the diversity of the genetic material involved in pancreatic carcinogenesis but 
also the variation between the abnormalities reported in different studies and between 
individual cases.
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1.3 Mitotic checkpoint proteins
The normal mitosis process (Fig. 1.5) is regulated by intricate mechanisms, among 
which the spindle assembly checkpoint plays a central role.
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The spindle assembly checkpoint is a feedback control that prevents cells with 
incompletely assembled spindles from continuing to mitosis (Fig. 1.6).
G2 Checkpoint
Spindle A ssem bly Checkpoint
G1 Checkpoint
Check for Cell s ize  
and DNA replication
Check for Cell size, 
Nutrients,Growth factors 
and DNA dam age
Resting 
state (Go)
Resting  
state
Check for C hrom osom e 
attachm ent to spindle
Figure l .6: The cell cycle includes Gl (synthesis of RNA proteins for DNA 
replication), S (synthesis of DNA) and G2 (synthesis of more RNA proteins) before 
proceeding to mitosis. The spindle assembly checkpoint controls the exit from the 
mitosis ensuring that all cells underwent a normal division of their DNA material
(http://oncogenesandcancer.wordpress.com/)
The molecular components of the checkpoint include M adl, Mad2, Mad3/BubRl, 
Bubl, Bub3, Mps l and Aurora B among other proteins (Musachio A et al., 2002, Yu 
H, 2002, Bharadwaj R et al., 2004).The checkpoint is activated when chromatids are 
not properly attached to both poles of the mitotic spindle. This leads to the inhibition of 
the ubiquitin ligase activity of the anaphase-promoting complex or cyclosome (APC/C) 
and the delay of the onset of anaphase (Yu H, 2006)(Fig. 1.7).
J S p
Securin  ^  Sister-Chromatid
Separase Separation
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Cyclin B ~ ► Mitotic Exit 
Cdkl
Figure 1.7: The mitotic spindle checkpoint which, when activated, inhibits the APC/C 
and delay sister chromatid separation (Yu H, 2006)
Mad2 (mitotic arrest deficiency 2) is recruited to the unattached kinetochores by
|  Spindle Checkpoint ON
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1 •
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M adl. When the checkpoint is active, Mad2 is relayed from the Madl-Mad2 complex 
to the mitotic checkpoint complex (MCC), a tetramer composed of BubRl, Bub3 and 
Mad2 bound to Cdc20. It then inhibits the APC/C through binding to its mitotic- 
specific activator, Cdc20. BubRl (budding uninhibited by benomyl related-1) also 
binds directly to Cdc20 and together with Mad2 are downstream components of the 
spindle checkpoint.
The genes that control Mad2 and BubRl are part of the genetic pathways involved 
in controlling the cell cycle and thus genetic defects at this level can lead to chromo­
some instability and tumorigenesis (Jallepalli P et al., 2001). Complete inactivation 
of the Mad2 and Bub3 leads to embryonic death in experiments with mice (Dobles M 
et al., 2000, Kalitsis P et al., 2000). Tissue cultures using cells where one allele of 
Mad2 has been inactivated show high rates of chromosome loss per generation and a 
high degree of aneuploidy (Michel L.S et al., 2001). One study observed that mice 
with heterozygous mutations in Mad2 develop normally but display lung tumour in 
adulthood, indicating a potential quantitative effect of Mad2 expression on tumorige­
nesis (Michel L.S et al., 2001). Mad2 mutations were also demonstrated in breast and 
bladder cancers (Percy et al., 2000, Hernando et al., 2001) while Madl mutations were 
seen in lung cancer (Nomoto et al., 1999) and Bubl mutations in lung and colorectal 
cancers (Gemma et al., 2000, Sato et al., 2000, Cahill et al., 1998).
BubRl mutations have been identified in human cancers like colon cancer (Weaver 
BA et al., 2006, Cahill DP et al., 1998) while studies on mice demonstrated that de­
creased levels of BubRl increase tumour incidence and progression (Babu JR et al., 
2003, Baker DJ et al., 2004, Dai W et al., 2004, Rao CV et al., 2005).
The abnormal proliferation of tumours results from the alteration of the genetic 
mechanisms responsible for the cell cycle checkpoints. Therefore the proteins linked 
to the mitotic checkpoint mechanism become potential molecular biomarkers for the 
invasive potential of a type of tumour.
As the carcinogenesis process involves abnormal changes in several mechanisms 
that control normal cell apoptosis and mitosis, the significance of a certain pathway 
varies from tumour to tumour. Chromosomal instability is one mechanism that defines 
carcinogenesis and it is closely linked to aberrations of the mitotic checkpoint mecha­
nism. Aneuploidy, in particular, as a direct result of abnormal mitosis, is correlated to 
changes in the levels of checkpoint proteins. Studies using mouse models have shown 
that decreased levels of Madl, Mad2, Bubl and BubRl and overexpression of Mad2 
result in increased rates of abnormal chromosome segregation (Dobles et al., 2000, 
Babu et al., 2003, Baker et al., 2004, Iwanaga et al., 2007, Jeganathan et al., 2007, 
Perera et al., 2007, Sotillo et al., 2007, Weaver et al., 2007).
Mad2 and BubRl proteins were included in this study as recognised major players 
in the checkpoint mechanism. Also the quantification and interpretation of their levels
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is well documented in the literature and clearly linked to the carcinogenesis process 
in different types of tumours: Mad2 in breast and bladder cancers (Percy et al., 2000, 
Hernando et al., 2001) and BubRl in lung and colorectal cancers (Gemma et al., 2000, 
Sato et al., 2000, Cahill et al., 1998). The time-limiting design of this pilot study did 
not allow the inclusion of other proteins involved in controlling the mitotic checkpoint 
mechanism.
Multiple different genetic pathways are involved in pancreatic carcinogenesis. Ab­
normalities seen in the chromosomal number set represents a contributing aspect to 
the overall tumour progression. Aneuploidy levels have the potential to become part 
of the individual tumour signature and part of the specific individual genetic profile 
increasingly employed in discovering personalized targeted therapies.
For the purposes of this study four chromosomes have been selected to investigate 
the levels of aneuploidy they display along the process of pancreatic carcinogenesis: 
chromosome 1, 6, 9 and 18. The rationale behind this selection lies with the evidence 
from the pancreatic cancer genome which includes these chromosomes but also with 
the known hypothesis that aneuploidy is, to some extent, a random event, therefore it 
can be illustrated in an extensive panel of chromosomes. The selected chromosome 
probes provided satisfactory fluorescent results in pancreatic cancer tissue compared 
to a larger panel trialled initially. Furthermore, 9p 21 is the locus for the p i6 gene 
and 18q21 is the locus for the SMAD4 gene, both proved to have a significant role 
in pancreatic cancer (Feldman G et al., 2007). However, the current study was not 
designed to investigate specific gene pathways.
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1.4 Objectives and Study plan
1.4.1 Objectives
1. Retrospectively assess aneuploidy levels in pancreatic intraepithelial lesions as­
sociated with pancreatic ductal adenocarcinoma. This would help establish a 
potential critical progression stage in carcinogenesis and allow the use of aneu­
ploidy in genotyping individual tumours.
2. Retrospectively assess the levels of mitotic checkpoint protein levels Mad2 and 
BubRl.
3. Correlate the aneuploidy and the mitotic checkpoint protein levels Mad2 and 
BubRl to patient data.
1.4.2 Study plan
1. Use fluorescence in situ hybridization to evaluate the aneuploidy levels in differ­
ent PanIN grades.
2. Use immunohistochemistry to evaluate the levels of mitotic checkpoint proteins 
Mad2 and BubRl in a panel of pancreatic intraepithelial lesions.
3. Use statistical correlation models to test for potential significant correlations be­
tween the aneuploidy levels and mitotic checkpoint proteins Mad2 and BubRl 
levels.
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Chapter 2
Aneuploidy in pancreatic 
intraepithelial lesions
2.1 Introduction
The method employed to score the chromosomal copy numbers was fluorescence in 
situ hybridization (FISH). FISH is a technique that uses fluorescently labelled DNA 
probes to detect chromosomal alterations in cells. It involves the preparation of short 
sequences of single-stranded DNA called probes, which are complementary to the 
DNA sequences to be investigated. These probes hybridize to the complementary 
DNA and, because they are labelled with fluorescent tags, they allow the quantification 
of chromosome copy numbers. There are two types of chromosome probes: chromo­
some enumeration probes (CEP), used to detect chromosomal number anomalies, and 
locus-specific indicator probes (LSI) used to investigate deletion or amplification of 
specific genes. FISH allows visualization of chromosomes in metaphase or interphase 
with numerical or structural anomalies with high sensitivity and specificity (Ried T et 
al., 1998).
The diagnostic applications include detecting gene amplifications (Her2 in breast 
cancer) (Bartlett J et al., 2001), gene rearrangements (BCR-Abl in leukemia) (Nolte 
M et al., 1996), viral infections (human papilloma virus) (Bartlett J, 2006). The ad­
vantages of the method are that it has a high specificity and sensitivity for the selected 
chromosome(s), that the chromosome probes used are widely available, that it is a 
validated diagnostic tool and that the automated method is time saving allowing for 
large numbers of specimens to be processed. The disadvantages are related to its use 
in tissues that present difficulties for optimizing the method, to intraobserver and in­
terobserver variation, to sectioning bias and to the limited number of probes used on 
the same tissue sample. FISH can be used for diagnostic cytology in bladder, lung, 
oesophagus and bile duct cancers (Hailing K et al., 2007).
FISH can only detect a known genetic aberration, provided the specific probe is
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available, in other words FISH cannot be used as a generic screening tool for unknown 
chromosome rearrangements (Speicher MR et al., 2005, Ried T et al., 1998), how­
ever advanced types of FISH can be used for 24-colour karyotyping: multiplex FISH 
(M-FISH) or spectral karyotyping (SKY). Both methods allow painting of the whole 
chromosome complement in a single hybridization by utilising different fluorophores. 
The fluorescence microscope used to capture the images has filter sets specific for par­
ticular fluorochromes and uses an algorithm to separate and identify the chromosomes 
which are visualized in characteristic colours. The difference between M-FISH and 
SKY lies in the method used to differentiate the labelled probes (Speicher MR et al., 
2005).
This validated method of detecting aneuploidy levels is already used in the base 
laboratory for detecting chromosome number changes in premalignant stages of oe­
sophageal and gastric cancer (Hilling K et al., 2007, Doak S et al., 2003, Cronin J et 
al., 2011, Williams L et al., 2005, Williams L et al., 2009).
This part of the study was designed to:
1. Identify pancreatic intraepithelial lesions (PanlNs 1-3) associated with PDAC in 
archival pancreatic tissue stored after pancreatic resection.
2. Quantify the levels of aneuploidy displayed by chromosomes 1, 6, 9 and 18 in 
different histological stages.
3. Demonstrate how aneuploidy changes with the PanIN grade.
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2.2 Materials and method
2.2.1 Sample characteristics
The specimens included in the study were obtained from the archive of the Histopathol- 
ogy department in Morriston Hospital, ABMU Health Board Swansea where they were 
stored after elective surgical resection in the local Pancreatic Unit, tertiary referral cen­
tre for South Wales. Ethical approval for the project was granted by the South West 
Wales Research Ethics Committee on the I I th November 2010.
30 patients were included in this study, 21 males and 9 females, median age 68.5 
years, range 53-82 years. All patients underwent pylorus-preserving pancreatico - duo- 
denectomy between 2010-2012. Specimens with any PanIN 1-3 in the resected PDAC 
specimen in 4 consecutive sections needed for the FISH treatment were included. The 
tissue sections displayed at least one type of PanIN lesion and often more than one 
type. Specimens with peripheral ducts with PanIN lesions which would not allow se­
quential sectioning and specimens from patients who underwent neoadjuvant therapy 
were excluded.
Positive and negative controls for pancreatic tissue were provided by the manufac­
turer together with the FISH reagents on request (Vysis, UK).
3 patients who underwent distal pancreatectomy for multiple congenital cysts, lympho- 
epithelial cyst and peritoneal pseudocyst, respectively, were included as normal con­
trols (Table 2.1).
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A total number of 68 histological lesions were identified including 3 normal ducts 
from non-malignant specimens, 22 normal ducts from PDAC specimens, 11 ducts with 
PanIN 1A, 12 ducts with PanIN IB, 7 ducts with PanIN 2, 7 ducts with PanIN 3 
and 8 ducts with PDAC. One lymph node metastasis noted on a PDAC specimen was 
included in one case analysis but excluded from the overall data analysis.
All the specimens included in this study had ductal adenocarcinoma but the aneu­
ploidy was not scored in the areas with adenocarcinoma, but in ducts away from the 
tumour to ensure that the premalignant stages were clearly not intraductal carcinoma.
The PanIN lesions were identified and graded by a Consultant Histopathologist 
with a special interest in pancreatic cancer into PanIN 1A, PanIN IB, PanIN 2 and 
PanIN 3 using standard histological criteria previously described in the literature (Hruban 
RH et al., 2004). The opinion of a second expert was requested and the results of both 
gradings are detailed in Table 2.2.
Table 2.2: Observer 1 and 2 grading of the histological stages in the specimens 
included in the study, the differences noted by observer 2 highlighted in red
# Main Pathology Observer 1 grading Observer 2 grading
1 Ductal adenocarcinoma head pancreas
PanIN IB PanIN IB + CA in duct
Squamous metaplasia PanIN IB + focus CA in duct
N N
2 IPMN no invasion
PanIN IB ?2 LGD in IPMN
PanIN IB LGD IN IPMN
N N
3 IPMN no invasion
? PanIN 2 PanIN 1A
PanIN IB PanIN IB and LGD in IPMN
N N
N = normal (duct); PanIN = pancreatic intraepithelial neoplasia; CA = carcinoma;
IPMN = intraductal pancreatic mucinous neoplasia; LGD = low grade dysplasia
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# Main Pathology Observer 1 grading Observer 2 grading
4 Ductal adenocarcinoma head pancreas
N N
PanIN 1A/1B PanIN IB
PanIN IB PanIN IB ?2
5 Ductal adenocarcinoma head pancreas
PanIN IB PanIN 3
N N
PanIN 2 PanIN 3
6 Ductal adenocarcinoma head pancreas
N N
7 Ductal adenocarcinoma head pancread
N N
N PanIN IB
8 Ductal adenocarcinoma head pancreas
PanIN 2 PanIN 2
N N and PanIN 1A
9 Cholangiocarcinoma
PanIN IB PanIN IB
10 Cholangiocarcinoma
N N
11 Ductal adenocarcinoma head pancreas
PanIN 3 CA
12 Ductal adenocarcinoma head pancreas
PanIN 1A PanIN 1A
N = normal (duct); PanIN = pancreatic intraepithelial neoplasia; CA = carcinoma;
IPMN = intraductal pancreatic mucinous neoplasia; LGD = low grade dysplasia
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# Main Pathology Observer 1 grading Observer 2 grading
13 Ductal adenocarcinoma head pancreas
PanIN 2 ?1B PanIN 2
N N
CA metastasis CA metastasis
14 Adenocarcinoma arising in IPMN
N N
PanIN 2 PanIN 2 + 3
15 Ampullary carcinoma
N N
PanIN 2 PanIN IB and 2
16 Ductal adenocarcinoma head pancreas
N N
PanIN 3/CA CA in duct
PanIN 1A PanIN IB
17 Ductal adenocarcinoma head pancreas
PanIN 1A PanIN IB
N N
18 Ductal adenocarcinoma head pancreas
N N
Squamous metaplasia PanIN 1 A/Squamous metaplasia
19 Ductal adenocarcinoma head pancreas
PanIN 1A PanIN IB
N N
20 Ductal adenocarcinoma head pancreas
PanIN 2 CA in duct
N = normal (duct); PanIN = pancreatic intraepithelial neoplasia; CA = carcinoma;
IPMN = intraductal pancreatic mucinous neoplasia; LGD = low grade dysplasia
35
# Main Pathology Observer 1 grading Observer 2 grading
21 Ductal adenocarcinoma head pancreas
PanIN IB PanIN IB
N N
22 Lympho-epithelial cyst
N N
23 Ampullary carcinoma. Deep pancreas invasion
N N
PanIN 2 PanIN IB
PanIN 3/CA CA in lymph duct
24 Ductal adenocarcinoma head pancreas
PanIN 2 CA in lymph duct?
PanIN IB PanIN IB
N N
25 Ductal adenocarcinoma head pancreas
PanIN 2 PanIN 2
PanIN IB PanIN IB
N N + PanIN IB
26 Ductal adenocarcinoma head pancreas
N N
PanIN 2 PanIN IB and 2
PanIN 3 CA in duct
CA CA
27 Duodenal carcinoma
PanIN 2 ?1B PanIN 2
N N
28 Endocrine tumour
N N
N = normal (duct); PanIN = pancreatic intraepithelial neoplasia; CA = carcinoma; 
IPMN = intraductal pancreatic mucinous neoplasia; LGD = low grade dysplasia
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# Main Pathology Observer 1 grading Observer 2 grading
29 Ampullary carcinoma
N
PanIN 1A
N
PanIN IB
30 Ampullary carcinoma
PanIN IB PanIN IB
31 Multiple congenital cysts
N N
32 Multiple congenital cysts
PanIN 1A PanIN IB
33 Adenocarcinoma arising in IPMN
PanIN 2 
CA
Intermediate grade dysplasia 
CA
34 Multiple congenital cysts
N N
35 Ductal adenocarcinoma
CA CA
36 Ductal adenocarcinoma
PanIN 2 
CA
PanIN 2 + CA in duct 
CA
37 Ductal adenocarcinoma
CA CA
38 Peritoneal pseudocysts
N N
N = normal (duct); PanIN = pancreatic intraepithelial neoplasia; CA = carcinoma;
IPMN = intraductal pancreatic mucinous neoplasia; LGD = low grade dysplasia
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# Main Pathology Observer 1 grading Observer 2 grading
39 Ductal adenocarcinoma
PanIN 3 CA in duct
PanIN 2 CA
PanIN 3 CA in duct
40 Ductal adenocarcinoma
CA CA
41 Multiple epithelial cysts (? acinar cell cystadenoma)
N N
42 Neuroendocrine carcinoma
PanIN 3 CA
CA CA
43 Ductal adenocarcinoma
CA CA
N = normal (duct); PanIN = pancreatic intraepithelial neoplasia; CA = carcinoma;
IPMN = intraductal pancreatic mucinous neoplasia; LGD = low grade dysplasia
There was agreement in all but one case for the normal ducts, in 84.2% for the 
PanIN 1, in 46.6% for the PanIN 2, in no case for the PanIN 3 and in all cases for the 
carcinoma stage. 5 out of 6 PanIN 1A lesions were classed by the second observer as 
PanIN IB. One PanIN IB was graded as PanIN 3 which highlights the fact that not only 
the macroscopic characteristics but also the topography related to the main tumour has 
to be included in the grading criteria. Over 50% of the PanIN 2 received a different or a 
mixed grading from the second observer, with some ducts displaying a lower or higher 
grade or even carcinoma. Noteworthy, most of the PanIN 3 lesions were classed by the 
second observer as intraductal carcinoma, which highlights the difficulties in isolating 
with confidence the late premalignant stages in a specimen with carcinoma. Only 
by surveying areas as distant as possible from the main tumour the grading of these 
premalignant lesions could be confidently done. Another method of differentiation 
would be by using molecular markers which could allow for confident grading. In 
this study, the final analysis was based on the grading provided by the first observer to 
ensure consistency with other linked studies. It is worth mentioning that in studies on 
dysplasia the concordance between experts is poor as measured by the inter-observer
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kappa values (k) and that there is no study of observer agreement between experts for 
PanlNs. k values higher than 0.60 indicate good and very good strength of agreement. 
Montgomery demonstrated the existing poor agreement in assessing Barrett’s dysplasia 
amongst a panel of international experts (ac=0. 15-0.32) (Montgomery et al., 2001).
39
2.2.2 Optimization
The protocol used in this study was optimized for pancreatic tissue starting from 
the validated FISH protocol used for diagnostic human epidermal receptor type 2 
(Her2/neu) gene status in breast cancer. The FISH assay is based on the gene copy 
number and the ratio between the numbers of Her2 and Chromosome 17 sequences 
(Wolff AC etal., 2007).
The mentioned protocol is a validated diagnostic protocol and has been used rou­
tinely for several years in the Graduate Entry Pathology Laboratory, Singleton Hos­
pital, Abertawe Bro Morgannwg University Health Board Swansea. The senior staff 
in the Pathology Laboratory demonstrated the protocol then supervised the first inde­
pendent run and was available for troubleshooting when needed throughout the project 
work. The final protocol used for pancreatic tissue followed the exact same steps with 
few adjustments highlighted in the description below.
The protocol consisted of the following steps:
1. The 4 fim  paraffin-embedded tissue sections on glass slides (Menzel-Glaser Su­
perfrost, Fisher Scientific UK Ltd) were baked overnight at 65°C.
2. De-waxing was achieved by placing the slides in two consecutive Xylene washes 
(Fisher Scientific UK Ltd) at room temperature (RT) for 10 minutes.
3. The slides were immersed in two consecutive 100% Industrial Methylated Spirit 
(IMS) washes (Fisher Scientific UK Ltd) for 5 minutes at RT.
4. Air dry stage.
5. The slides were immersed in consecutive solutions 100% IMS, 85% IMS and 
70% IMS for 1 minute each at RT.
The 85% IMS solution was prepared by mixing 85 mL 100% IMS and 15 mL 
distilled water (H20 2). The 70% IMS solution was prepared by mixing 70 mL 
100% IMS and 30 mL H20 2. Between uses, the solutions were kept tightly 
covered at room temperature. The unused stock was discarded after 6 months
(www. abbottmolecular . com).
6. The slides were immersed in H20 2 for 1 minute at RT.
7. Acid permeabilisation was achieved by placing the slides in 0.2N hydrogen chlo­
ride (HC1) solution (Sigma-Aldrich Co UK) for 20 minutes at RT.
8. The slides were immersed in H20 2 for 3 minutes at RT.
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9. The slides were immersed in wash buffer (Vysis Paraffin Pretreatment IV & 
Post-Hybridization Wash Buffer Kit, Abbott Molecular England) for 3 minutes 
atRT.
The wash buffer solution was provided by the manufacturer (Abbott Molecu­
lar England) and represented a 2X SSC/0.1% NP-40 Wash Solution. It can be 
prepared by mixing vigorously 100 mL 20X SSC (pH 5.3) and 850 mL H20 2 
and then adding 1 mL NP-40. The solution pH was adjusted to 7.0 ±  0.2 us­
ing sodium hydroxide (NaOH). H20 2 was added to bring the final volume to 
1L. The solution was stored in a covered container at room temperature. The 
unused solution was discarded after 6 months or earlier if it appeared cloudy or 
contaminated.
10. The slides were placed in glass Coplin jars (Thermo Scientific, Fisher Scientific 
UK Ltd) containing the pre-treatment solution (8% sodium thiocyanate) (Vysis 
Paraffin Pretreatment IV & Post-Hybridization Wash Buffer Kit, Abbott Molec­
ular England) in a water bath (VWR 1229 Water Bath, VWR International UK) 
at 80°C for 30 minutes. The glass Coplin jars (Thermo Scientific, Fisher Scien­
tific UK Ltd) containing the solution were placed in the cold water bath and the 
temperature was increased gradually to avoid the glass cracking/breaking before 
the slides were added.
11. The slides were immersed in H20 2 for 1 minute at RT.
12. The slides were immersed in wash buffer (Vysis Paraffin Pretreatment IV & 
Post-Hybridization Wash Buffer Kit, Abbott Molecular England) twice for 5 
minutes at RT.
13. The slides were placed in glass Coplin jars containing a protease solution with 
0.005% pepsin enzyme (Vysis Paraffin Pretreatment IV & Post-Hybridization 
Wash Buffer Kit, Abbott Molecular England) added approximately 5 minutes to 
the protease buffer (Vysis Paraffin Pretreatment IV & Post-Hybridization Wash 
Buffer Kit, Abbott Molecular England) before introducing the slides. The slides 
were kept in the jars in a water bath (VWR 1229 Water Bath, VWR International 
UK) at 37°C for 30 min. This represented the digestion phase required to allow 
probe access by opening up the cytoplasm. It was one of the critical stages as 
suboptimal digestion impacts on the final scoring.
When a new protease batch was used, the protocol included an additional stage 
to ensure optimal digestion: the product used for nuclear staining (in this case, 
DAPI III Counterstain, Abbott Molecular England) was added to the slides and 
cover slips were applied; the slides were examined under the microscope -  usu­
ally, optimal digestion was illustrated by homogeneously stained nuclei which
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looked slightly swollen compared to under-digested tissue; suboptimal diges­
tion could appear as heterogeneous nuclear staining while over-digestion was 
demonstrated by damaged nuclear membranes. In case of insufficient digestion, 
the cover slips could be removed and the slides added to the protease buffer 
for extra time until optimal digestion was achieved. In case of over-digestion, 
the slides could not be reliably scored so they were discarded and fresh tissue 
sections were used to restart the protocol using a reduced digestion stage until 
optimal digestion was achieved.
The time interval for the digestion stage was readjusted repeatedly in the opti­
mization phase until an optimal time of 30 min for PDAC tissue digestion was 
reached.
14. The slides were dipped in wash buffer (Vysis Paraffin Pretreatment IV & Post- 
Hybridization Wash Buffer Kit, Abbott Molecular England) for 5 times at RT.
15. The slides underwent fixation in neutral buffered formol saline solution (Sigma- 
Aldrich Co UK) for 10 minutes at RT.
16. The slides were immersed in wash buffer (Vysis Paraffin Pretreatment IV & 
Post-Hybridization Wash Buffer Kit, Abbott Molecular England) for 5 minutes 
atRT.
17. The slides were immersed consecutively in 70% IMS, 85% IMS and 100% IMS 
for 1 minute each at RT.
18. Air dry stage.
19. The slides were placed in glass Coplin jars containing 70% Formamide solution 
in a water bath (VWR 1229 Water Bath, VWR International UK) at 72°C for 7 
min. The glass Coplin jars (Thermo Scientific, Fisher Scientific UK Ltd) con­
taining the solution were placed in the cold water bath and the temperature was 
increased gradually to avoid the glass cracking/breaking before the slides are 
added. After use, the solution was discarded using the toxic products handling 
protocol in the toxic waste container which was collected regularly for disposal 
as per toxic waste protocol. This stage represented the denaturation of DNA 
stage whereby the DNA double strand was separated into single strands to allow 
hybridization with the probe in the hybridization stage. The 70% Formamide 
solution was prepared in a fume hood using the toxic products handling proto­
col, by mixing 49 mL ultrapure formamide (Fisher Scientific UK Ltd) stored in 
the toxic products compartment, 7 mL 20X SSC (pH 5.3) and 14 mL H20 2 in 
a glass Coplin jar (Thermo Scientific, Fisher Scientific UK Ltd). The pH was 
measured using a pH meter with a glass electrode to ensure pH was 7.0-8.0. The
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solution was stored between uses in a secured container in the toxic products 
compartment at 2-8°C. It was discarded after 7 days.
The time interval for the denaturation stage was readjusted repeatedly in the 
optimization phase until an optimal time of 5 min for PDAC tissue was reached.
20. The slides were dipped in H20 2 x 5 times at RT in the fume hood. After use, 
the H20 2 was discarded using the toxic products handling protocol in the toxic 
waste container.
21. The slides were immersed consecutively in 70% IMS, 85% IMS and 100% IMS 
for 1 minute each at RT in the fume hood. After use, the 70% IMS and 85% IMS 
solutions were discarded using the toxic products handling protocol in the toxic 
waste container.
22. Air dry in the fume hood.
23. The chromosome probe mixture was added to each slide in the fume hood, ensur­
ing minimal exposure to light to prevent degradation of the fluorescence. Also, 
uniform coverage of the relevant area of the tissue section was vital.
The probes used were centromeric enumeration probes (CEP) (fluorophore-labeled 
enumerator probe and blocking DNA in Tris-EDTA buffer) for chromosomes 1 
(band region lp l 1-qll, locus D1Z5, Orange), 6 (band region 6p l 1.1-ql 1, locus 
D6Z1, Green), 9 (band region 9pl 1-qll, Green) and 18 (band region 18pl 1.1- 
ql 1.1, locus D18Z1, Orange) (Vysis, UK).
The composition of the probe mixture was repeatedly readjusted during the opti­
misation phase until an optimal formula was reached to ensure satisfactory scor­
ing. We used 2 /il of each CEP probe and 6 /A of CEP hybridization buffer 
(Dextran sulphate, Formamide, SSC)(Vysis, UK). They were stored at -20°C 
prior to use.
24. Cover slips were applied, most commonly 22 x 30 mm (Menzel-Glaser, Fisher 
Scientific UK Ltd) but occasionally of a different size depending on the size of 
the relevant tissue section.
25. The cover slips were sealed in place using commercial rubber solution (Halfords 
Group pic) applied in a thin layer on the margins and on the adjacent area of the 
glass slide. Minimal exposure to light was ensured during this stage.
26. The slides were then placed in a pre-warmed Hybrite (Vysis Slide Stainer, Ab­
bott Molecular England) and incubated for 16 hours overnight at 37°C.
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27. The slides were removed from the Hybrite promptly after the 16 hours and the 
rubber seal was gently removed to prevent any movement of the cover slip and 
with minimal exposure to light.
28. The slides were immersed in posthybridization wash buffer (Vysis Paraffin Pre­
treatment IV & Post-Hybridization Wash Buffer Kit, Abbott Molecular Eng­
land), protected from direct light, until the cover slips became loose and were 
removed.
29. The slides were placed in glass Coplin jars containing posthybridization wash 
buffer (Vysis Paraffin Pretreatment IV & Post-Hybridization Wash Buffer Kit, 
Abbott Molecular England) in a water bath (VWR 1229 Water Bath, VWR 
International UK) at 72°C for 2 minutes in the fume hood. The glass Coplin 
jars (Thermo Scientific, Fisher Scientific UK Ltd) containing the solution were 
placed in the cold water bath and the temperature was increased gradually to 
avoid the glass cracking / breaking before the slides were added.
30. The slides were rinsed vigorously for 10-15 seconds in the hot fluid from the pre­
vious stage which had been transferred to a wash pot. This stage was important 
to ensure any redundant superfluous chromosome probe was washed off.
31. The slides were immersed in fresh posthybridization wash buffer (Vysis Paraf­
fin Pretreatment IV & Post-Hybridization Wash Buffer Kit, Abbott Molecular 
England) for 2 minutes at RT, protected from direct light.
32. The slides were dipped in 70% IMS at RT.
33. Air dry in the dark.
34. 10 /d DAPI III Counterstain (Abbott Molecular England) was added to each 
slide as a contrast media for the nucleoplasm, ensuring uniform coverage of the 
relevant tissue area and minimal exposure to light.
We used 10 ^1 of Vectashield Antifade 4', 6-diamidino-2-phenylindole (DAPI) 
125 /ig/ml (Vector Laboratories, Inc. Burlingame, CA 94010) for each section 
with satisfactory results.
35. Cover slips were applied, most commonly 22 x 30 mm (Menzel-Glaser, Fisher 
Scientific UK Ltd) but occasionally of a different size depending on the size of 
the relevant tissue section. They were fixed in place using commercial adhesive 
products (i.e. clear nail varnish).
36. The slides were stored in the dark until scoring.
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Negative and positive control sections were included in the treatment algorithm 
with each set of tissue sections. The negative control was represented by a tissue 
section from one of the breast cancer specimens included in the treatment which did 
not have the fluorescent probe added to it. The positive control was represented by a 
tissue section from a breast cancer specimen which had previously been treated and 
scored according to the manufacturer’s instructions.
2.3 Results
The work for the present study was performed on formalin-fixed paraffin embedded 
(FFPE) archival tissue sections from tissue blocks obtained after elective surgical re­
section for malignant or benign pancreatic disease and stored in the Histopathology 
Department, Morriston Hospital, ABMU Health Board Swansea.
Each set of sections was accompanied by a haematoxylin and eosin stained sec­
tion from the same tissue block which was used to identify and match the relevant 
histopathological structures with the sections used for FISH (Fig. 2.1-2.6).
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(a) H aem atoxylin -eosin  (H E) section  x 10 show ing the ductal ce lls  in a single layer
(b) FISH section  x 6 0  seen with DAPI filter show ing a fragment o f  the duct with  
CEP 6 green signals, CEP 1 orange signals, DAPI blue cells  nuclei and non-specific  
cytoplasm ic uptake in the strom al la y e r .
Figure 2.1: Tissue section from a normal specimen; the relevant duct and the 
surrounding stroma highlighted on the HE section; the CEP signals and relevant 
histological structures highlighted on the FISH section.
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PanIN 1A duct
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(a) H aem atoxylin-eosin  (H E) section  x 10 show ing the ductal ce lls  in a single layer 
with m ucin accum ulation at the apical pole.
(b) FISH section x 6 0  seen with DAPI filter show ing a fragm ent o f  the duct with  
CEP 9 green signals, CEP 18 orange signals, DAPI blue c e lls  nuclei and non-specific  
cytoplasm ic uptake in the stromal layer as w ell as the m ucin layer.
Figure 2.2: Tissue section from a specimen with PanIN 1 A; the relevant duct and the
surrounding stroma highlighted on the HE section, ; the CEP signals and relevant
histological structures highlighted on the FISH section.
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(a) H aem atoxylin-eosin  (H E) section x 10 show ing the duct with areas o f  m ultilay­
ered ce lls  with m ucin accum ulation at the apical pole.
(b) FISH  section  x 6 0  seen with DAPI filter sh ow ing  a fragm ent o f  the duct with  
CEP 6 green signals, CEP 1 orange signals, DAPI blue ce lls  nuclei and non-specific  
cytoplasm ic uptake in the stromal layer.
Figure 2.3: Tissue section from a specimen with PanIN IB; the relevant duct and the
surrounding stroma highlighted on the HE section, ; the CEP signals and relevant
histological structures highlighted on the FISH section.
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PanIN 2 duct
(a) H aem atoxylin-eosin  (H E) section x lO  show ing the m ultilayered ductal cells  
with m ucin accum ulation at the apical pole
PanIN 2 duct mucin
nuclei
stroma
(b) FISH section x 6 0  seen with DAPI filter show ing a fragment o f  the duct with  
CEP 9 green signals, CEP 18 orange signals, DAPI blue cells  nuclei and non-specific  
cytoplasm ic uptake in the stromal layer as w ell as the m ucin layer.
Figure 2.4: Tissue section from a specimen with PanIN 2; the relevant duct and the
surrounding stroma highlighted on the HE section, ; the CEP signals and relevant
histological structures highlighted on the FISH section.
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(a) H aem atcxylin -eosin  (H E ) section x 10 show ing the m ultilayered ductal cells  
with som e desquam ation from  the top layer and m ucin accum ulation at the apical 
pole.
PanIN 3 duct
nuclei
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(b) FISH section  x 6 0  seen with DAPI filter show ing a fragment o f  the duct with  
CEP 9 green signals, CEP 18 orange signals, DAPI blue ce lls  nuclei and non-specific  
cytoplasm ic uptake in the stromal layer as w ell as the m ucin layer.
Figure 2.5: Tissue section from a specimen with PanIN 3; the relevant duct and the
surrounding stroma highlighted on the HE section, ; the CEP signals and relevant
histological structures highlighted on the FISH section.
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Ducts with PDAC
(a) H aem atoxyiin-eosin  (H E) section x lO  show ing m ultiple ducts with distorted  
architecture.
(b) FISH section x 6 0  seen with DAPI filter show ing one duct with CEP 6 green  
signals, CEP 1 orange signals, DAPI blue ce lls  nuclei and non-specific  cytop lasm ic  
uptake.
Figure 2.6: Tissue section from a specimen with PDAC; the relevant ducts highlighted 
on the HE section; the CEP signals and relevant histological structures highlighted on
the FISH section.
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After completing the treatment the sections were assessed to ensure adequate di­
gestion and hybridization. If suitable, they were then scored manually for aneuploidy 
using a Zeiss Axio Imager Z1 Fully Motorised Upright microscope with M etaSystems 
Isis FISH imaging software, equipped with DAPI, Spectrum Green and Spectrum Or­
ange filters.
The principal investigator performed all the steps in the manual protocol for FISH 
treatment and underwent training for manual scoring using the fluorescent microscope. 
200 nuclei were scored, on average, in each histological area of interest and the number 
o f chromosome copies was documented in different categories: one copy (deletion), 
two copies (diploid), more than two copies (amplification). The scoring was done for 
each of the four chromosome probes.
The main end points in the study were the overall aneuploidy score (mean percent­
age of aneuploid cells in a pancreatic duct displaying a certain histological stage), the 
level of deletions (mean percentage of cells with chromosomal deletions in a pancre­
atic duct displaying a certain histological stage) and the level of amplifications (mean 
percentage of cells with chromosomal amplifications in a pancreatic duct displaying 
a certain histological stage). The results for each category were entered into statisti­
cal analysis to uncover potential significant variations between different histological 
stages. A total of 146000 cells have been scored. Occasionally the architecture of 
the pancreatic ducts with advanced premalignant lesions precluded confident scoring 
because of overlapping of the nuclei and those areas have been excluded to avoid over­
scoring for amplifications (Fig. 2.7).
Duct with PDAC
nuclei
Figure 2.7: Area with overlapping nuclei in a pancreatic duct with adenocarcinoma 
after hybridization with dual probe CEP 1 (Orange signals) and CEP 6 (Green 
signals); the blue staining is the result of nuclear staining with DAPI; the green 
internuclear staining represents non-specific cytoplasmic uptake.
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2.3.1 Statistical analysis
The final results were divided into overall, average and individual levels of chromo­
somal abnormalities (aneuploidy, amplifications and deletions, respectively) for chro­
mosomes 1, 6, 9 and 18.
The final results were processed using Microsoft Excel 2007 and IBM SPSS Statis­
tics version 2011. The Student paired t-test was used to uncover potential significant 
differences between paired histological stages as reflected in the levels of overall aneu­
ploidy, deletions and amplifications. The one-way analysis of variance (ANOVA) was 
used to determine the differences across all the histological groups. Significance was 
attributed to a p- value less than 0.05.
Several case studies were included to illustrate individual patterns for aneuploidy 
progression in individual tumours.
The scoring results for overall aneuploidy, overall amplifications and overall dele­
tions for each chromosome in different histological stages were introduced respectively 
in statistical analysis using Student paired t-test to determine significant differences be­
tween different histological stages (Table 2.3).
Table 2.3: Statistical analysis using Student paired t-test to compare pairs of 
histological groups for each chromosome for overall aneuploidy, overall 
amplifications and overall deletions. Only significant results (*) represented by
/?<0.05 are documented.
Normal/
Normal
Specimens
Normal/
Cancer
Specimens
PanIN 1 PanIN 2 PanIN 3
Ch
ro
m
os
om
e 
1
PanIN 1
PanIN 2
PanIN 3 p=0 . 0 0 2
^amplifications
p = 0 . 0 0 0 9
^amplifications
PDAC p=0 . 0 0 2
* aneuploidy
p=0 . 0 2 4
^amplifications
/? = 0 .0 1 4
*aneuploidy
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2.3.1.1 Overall aneuploidy
The overall aneuploidy levels for each chromosome probe in a histological lesion re­
sulted from the sum of the deletions percentage and the amplifications percentage cor­
responding to the lesion. To investigate the overall aneuploidy trend in various his­
tological stages the corresponding results were averaged for each stage and for each 
chromosome, respectively (Fig. 2.8).
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Figure 2.8: Overall number of aneuploid cells (mean%) for chromosomes 1, 6, 9 and 
18, respectively, scored in progressive histological stages and demonstrating an 
increasing trend towards PDAC.
The background level of overall aneuploidy found in normal ducts from the normal 
specimens was subtracted from the overall aneuplody level found in the normal ducts 
in the PDAC specimens as well as in PanIN 1, PanIN 2, PanIN 3 and PDAC to reflect 
the level displayed by the premalignant stages (Fig. 2.9).
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Figure 2.9: Adjusted number of aneuploid cells (mean%) for chromosomes 1, 6, 9 
and 18, respectively, scored in progressive histological stages and demonstrating an
increasing trend towards PDAC.
The adjusted overall aneuploidy levels showed that, as expected, the levels are very 
low for all chromosomes in normal ducts and PanIN 1A lesions, displaying negative 
values as well compared to normal specimens. PanIN IB lesions showed an increase 
in the level of overall aneuploidy compared to normal and PanIN 1A stages, while 
in PanIN 2 the upward trend continued. The PanIN 3 stage seems to reflect the most 
significant increase for most of the chromosomes analysed and in the last stage, PDAC,
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the trend remained constant. For chromosome 1 there was a sharp increase in PDAC, 
while the levels for chromosome 6 projected an almost linear trend at 12% ±  2%. The 
overall chromosome 9 aneuploidy was very low up to the PaIN 3 stage but higher in 
PDAC. The most consistent upward trend was revealed by the overall aneuploidy levels 
in chromosome 18, with a marked increase in PanIN 2 compared to the early stages 
and a further increase in PanIN 3. PDAC displayed similar values compared to PanIN
3.
2.3.1.2 Average aneuploidy
In order to gain insight into the particularities of the histological stages found in the 
cases included in the current study, the level of average aneuploidy was calculated 
(Fig. 2.10). This was obtained by averaging the proportion of aneuploid cells across 
all chromosomes analysed, in ducts with a particular histological stage corresponding 
to a single specimen. Example: specimen number 3 included 2 normal ducts, 2 ducts 
with PanIN IB, one duct with PanIN 2 and one duct with PanIN 3. The average 
aneuploidy in this specimen for normal ducts was the average between the 2 normal 
ducts across chromosomes 1, 6, 9 and 18, for PanIN IB, the average between the 2 
ducts with PanIN IB and for the lone ducts with PanIN 2 or 3 was the average across 
the 4 chromosomes in the singular duct.
Average aneuploidy
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Figure 2.10: The average number o f aneuploid cells (mean%) across the histological 
entities analysed; each vertical bar represents the range of aneuploidy across all 
chromosomes (mean%); each point on the graph represents a duct with the 
corresponding histological grade as listed in lower legend.
Each specimen displayed an individual trend between different histological stages, 
generally starting on a baseline in PanIN 1 and PanIN 2 and increasing in PanIN 3 
and PDAC. The specimens with advanced stages (PanIN 3, PDAC) had a higher level 
of average aneuploidy compared to specimens containing only early stages (PanIN 1,
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PanIN 2). There was a noticeable wide range of scores for aneuploidy in the PanIN 3 
lesions for the different chromosome probes. The average aneuploidy in PDAC was 
significantly higher compared to all the other stages (/;=0.002 vs normal ducts from 
normal specimens, p= 0 .013 vs PanIN 2,/?=0.028 vs PanIN 3). Also, the levels seen in 
PanIN 3 were significantly higher when compared to the normal ducts (/?=0.001) and 
to the levels in PanIN 1 (p=0.025). Even at the PanIN 2 stage there was a significant in­
crease when compared to the normal ducts (p -0.036). This confirmed that aneuploidy 
in all the chromosomes investigated in this study increased with the histological stage.
2.3.1.3 Overall amplifications
Amplifications were a significant molecular event in any histological stage and they 
had not been adjusted in relation to the normal specimens. They were less likely to 
be influenced significantly by sectioning bias and were more common in the advanced 
premalignant stages (Fig. 2.11).
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Figure 2.1 1: Overall number of cells with amplifications (%) for chromosomes 1, 6, 9 
and 18, respectively, scored in progressive histological stages; stationary trend in 
normal/cancer - PanIN IB; increase particularly in PanIN 2 - PanIN 3 for 
chromosomes 1 and 9 and in PanIN 3 - PDAC for chromosomes 6 and 18.
The trend for amplifications displayed a positive trend consistent across all the 
chromosomes investigated. The average levels in PanIN 1 across all probes reached 
0.79% (range 0-13.72%) while in PanIN 3 was calculated at 12.69% (range 0.14- 
76.62%) and in PDAC at 20.14% (range 0.59-63.02%).
The levels seen for chromosome 6 were significantly lower (/?=0.013) than for the 
other chromosomes but the trend was the same. Chromosome I showed a significant 
increase coresponding to PanIN 3 stage (PanIN 3 vs PanIN 1, p=0.0009) and PDAC 
(PDAC vs PanIN 2, p=0.024), in a similar fashion to chromosome 18 (PanIN 3 vs 
PanIN 1, p=0.002). The amplifications score for chromosome 9 reached the maximum 
value in PDAC while in the other stages remained low.
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Each of the chromosomes included in the study: 1, 6, 9 and 18, displayed an indi­
vidual trend in overall aneuploidy as well as deletions and amplifications. Generically, 
all o f them showed a positive trend in chromosome abnormalities as the histological 
stage approaches the PDAC stage, as shown previously, but further analysis revealed 
specific characteristics for each probe.
2.3.1.4 Average amplifications
The levels of amplifications calculated as an average across all chromosome probes 
for each histological type in each specimen included in the study (Fig. 2.12) remained 
close to zero in the early stages including PanIN 2 (range 0-5.99%, one outlier value 
at 27.53% in a PanIN 2 duct close to tumoural glands). This was also reflected in 
the statistical analysis using the Student’s paired t-test which showed no significant 
difference between the various early stages.
A change in the amplifications levels and trend became apparent at the PanIN 3 
stage where there was a significant increase when comparing the advanced stage with 
the values found in the normal ducts from PDAC specimens (/?=0.00l) and PanIN 1 
(/?=().002). A similar pattern was seen in the values calculated for PDAC where the 
Student's paired t-test returned significant results for differences between PDAC and 
normal ducts in normal specimens (y?=0.18) and PDAC and PanIN 2 (p=0.018).
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Figure 2.12: The average number of cells with amplifications (mean%) across the 
histological entities analysed; each vertical bar represents the range of amplifications 
across all chromosomes (mean%); each point on the graph represents a duct with the 
corresponding histological grade as listed in lower legend.
The range of values found in the initial stages clustered around the calculated av­
erage displaying minimal variations. In contrast, at PanIN 3 and PDAC the values 
showed a much wider range, supporting the theory that each tumour clone carries in­
dividual patterns of aneuploidy, specifically reflected in the levels of amplifications.
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2.3.1.5 Overall deletions
There was a high level of deletions in all histological stages, mainly in the early stages: 
normal duct, PanIN 1 and PanIN 2 (Fig. 2.13). In the advanced premalignant stages 
(PanIN 3) and in PDAC, the deletions did not prevail in the overall aneuploidy in all 
chromosomes investigated. In those lesions, amplifications typically appeared more 
significant than deletions, signaling a shift in the process of carcinogenesis.
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Figure 2.13: Overall number o f cells with deletions (mean%) for chromosomes 1, 6, 9 
and 18, respectively, scored in progressive histological stages and demonstrating a 
relatively stationary trend towards PDAC.
The percentage of deletions found in normal ducts from normal specimens was 
considered as background level, as before for overall aneuploidy, and used to adjust 
the level of deletions in the precancerous stages and PDAC (Fig. 2.14).
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Figure 2.14: Adjusted number of cells with deletions (mean%) for chromosomes 1, 6, 
9 and 18, respectively, scored in progressive histological stages.
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The percentage of deletions in normal ducts and PanIN 1A were comparable to 
the results from the normal ducts in normal specimens suggesting that this type of 
chromosomal abnormality was not significant in the early stages. Generically, the 
percentage increased in advanced stages but there was no uniform positive trend. For 
chromosome 1 the level of deletions reached a negative value when adjusted against 
the normal specimens, reflecting sectioning bias and confirming that deletions were 
not a hallmark of the carcinogenesis in this scenario. For chromosome 6 the trend 
increased up to 14% in PanIN 3 while, comparatively, the level for chromosome 9 in 
the same histology was at -0 .99% . For chromosome 18 the adjusted level of deletions 
was consistently around 8% in PanIN IB, PanIN2 and PanIN 3, reflecting a different 
trend compared to the other chromosomes.
2.3.1.6 Average deletions
The average level of deletions found in each type of histology from the specimens 
included in the study displayed a variable trend between different specimens but re­
mained within a set pattern across all stages. The range of values was also stable 
throughout the various stages (range 19.53% (PanIN 3)-52.66% (PanIN 2)) (Fig. 2.15).
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Figure 2.15: The average number o f cells with deletions (mean%) across the 
histological entities analysed; each vertical bar represents the range of deletions 
across all chromosomes (mean%); each point on the graph represents a duct with the 
corresponding histological grade as listed in lower legend.
Statistical analysis using the Student’s paired t-test confirmed that the average level 
of deletions did not change significantly between the different histological stages.
2.3.1.7 Chromosome 1
Aneuploidy in chromosome 1 increased with the histological stage, reaching the max­
imum value in PDAC. Amplifications followed a clear positive trend up to a maximum
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in PDAC. For deletions, the levels were variable in different histological stages, with a 
maximum in the PanIN 2 stage (Fig. 2.16). The mean level of deletions in each of the 
different histological stages was high (29.15% in normal duets from PDAC specimens, 
28.89% in PanIN 1A, 35.72% in PanIN IB, 39.18% in PanIN 2, 22.29% in PanIN 3 
and 32.73% in PDAC). Despite the fact that deletions were subject to bias, the trend 
in different histological stages still provided valuable insight into tumour progression. 
The level of amplifications in normal ducts was 2.63%, in PanIN 1A 4.19%, in PanIN 
IB 1.98% and in PanIN 2 6.51%, while in PanIN 3 it reached 22.39% and in PDAC 
29.23%.
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Figure 2.16: Overall number of aneuploid cells, cells with deletions and cells with 
amplifications (mean%) displayed by chromosome 1 in progressive histological 
stages; increasing trend towards PDAC for overall aneuploidy and amplifications; * 
indicates stages with statistically significant differences (/}-value<0.05) compared
with preceding stages
Basic statistical analysis using Student’s paired t-test confirmed significant dif­
ferences in the levels of overall aneuploidy between PDAC and normal specimens 
(p=0.002) as well as between PDAC and PanIN 2 stage (y?=0.014) and PDAC and 
PanIN 3 stage (p=0.041). Significant differences were also found in the levels of am ­
plifications between PanIN 3 and normal ducts from PDAC specimens (j?=0.001), be­
tween PanIN 3 and PanIN 1 (p=0.0009) and between PDAC and PanIN 2 (p=0.024). 
PanIN 3 appears to be a significant stage where chromosome 1 has a high level of 
amplifications.
Chromosome 1 showed a significant level of aneuploidy in PDAC as well, par­
ticularly amplifications, as confirmed by advanced statistical analysis using one-way 
ANOVA analysis comparing PDAC to normal ducts in normal specimens (/?=0.043, 
95% CI=0.59-47.89).
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2.3.1.8 Chromosome 6
The levels of overall aneuploidy in chromosome 6 followed a different trend compared 
to chromosome 1 (Fig. 2.17). They were relatively high in the normal ducts from 
PDAC specimens (mean 38.87%, range 24.70-68.05%), PanIN 1A (mean 39.37%, 
range 17.77-66.66%) and PanIN IB (mean 49.94%, range 30.97-82.60%) and showed 
no increase in PanIN 2 (mean 49.15%, range 43.21-56.20%) or the advanced stages: 
PanIN 3 (mean 53.75%, range 37.76-79.03%) and PDAC (mean 52.05%, range 43.80- 
62.12%). The overall aneuploidy for chromosome 6 was mainly represented by dele­
tions. In virtually all histological stages the levels of deletions followed a similar trend 
as the levels of overall aneuploidy.
The levels of amplifications for chromosome 6 remained low in PanIN 1 (mean 
3.03%, range 0-11.18%), PanIN 2 (mean 1.07%, range 0-5.51%) and even PanIN 3 
(mean 2.21%, range 0-7.69%) but displayed a sharp increase in PDAC (mean 7.92%, 
range 0.59-24.40%).
Statistical analysis (Student’s paired t-test) demonstrated a significant increase in 
the level of overall aneuploidy in PanIN 3 and PDAC when compared with normal 
ducts from normal specimens (p=0.029, /?=0.044 respectively) and normal ducts from 
PDAC specimens (/}=0.007, /?=0.043 respectively). The levels of amplifications in 
PDAC displayed a significant increase compared to normal ducts from PDAC spec­
imens (p=0.0004), PanIN 1 (p=0.004) and PanIN 2 (y;=0.049). Also, the level of 
deletions in PDAC was significantly higher compared to normal ducts from normal 
specimens (p=0.028).
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Figure 2.17: Overall number of aneuploid cells, cells with deletions and cells with 
amplifications (mean%) displayed by chromosome 6 in progressive histological 
stages; increasing trend towards PDAC for amplifications; * indicates stages with 
statistically significant differences (/?-value<0.05) compared with preceding stages.
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The advanced analysis using the one-way ANOVA mean comparison test showed 
no significant overall difference between histological stages in deletions levels. How­
ever, Dunnett T3 test comparing means in each stage with all the other stages revealed 
a significant difference between PanIN 2 and normal ducts from normal specimens 
(p=0.004, 95%CI=4.67-17.13) as well as between PDAC and normal ducts from nor­
mal specimens (/?=0.035, 95% CI=0.52-15.42). For amplifications, the ANOVA mean 
comparison test showed a significant overall difference between groups (p=0.002) but 
no similar results were seen when applying the Dunnett T3 test to the data.
2.3.1.9 Chromosome 9
The levels of overall aneuploidy concerning chromosome 9 remained stable in all 
histological stages including PanIN 3 and then increase in PDAC (Fig. 2.18). In 
the same premalignant stages the aneuploidy was mainly represented by deletions 
which reached a relatively high level in every stage in PDAC specimens: normal 
ducts (mean 38.26%, range 14.59-74.66%), PanIN 1A (mean 41.96%, range 30.30- 
64.46%), PanIN IB (mean 45.96%, range 25.47-60.38%), PanIN 2 (mean 40.66%, 
range 22.94-60.33%) and PanIN 3 (mean 41.75%, range 20.71-59.64%). In PDAC the 
levels were comparable to the levels in the premalignant stages (mean 42.40%, range 
13.88-72.14%).
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Figure 2.18: Overall number of aneuploid cells, cells with deletions and cells with 
amplifications (mean%) displayed by chromosome 9 in progressive histological 
stages; increasing trend towards PDAC for overall aneuploidy and amplifications; * 
indicates stages with statistically significant differences (/>value<0.05) compared
with preceding stages.
The levels of amplifications for chromosome 9 displayed an increase in PanIN 
2 (mean 3.98%, range 0-25.08%) compared to normal ducts (mean 1.02%, range 0-
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10.04%), PanIN 1A (mean 0.72%, range 0-6.51%) and PanIN IB (mean 0.38%, range 
0-2.29%). In PanIN 3 the levels did not follow the positive trend (mean 2.77%, range 
0.23-11.94%) but there was a sharp increase in PDAC (mean 17.54%, range 1.28- 
48.61%).
Statistical comparison using Student’s t-test illustrated the significant difference 
that the levels of overall aneuploidy display in the cancerous stage compared to all 
the precursor stages: normal ducts in normal specimens (y?=0.025), normal ducts in 
PDAC specimens (y?=0.001), PanIN 1 (/>=0.005), PanIN 2 (p=0.007) and PanIN 3 
(p=0.016). For amplifications, a significant increase is noted in PDAC compared to 
PanIN 3 (y?=0.033) and normal ducts from PDAC specimens (p=0.0001). Also, at 
PanIN 3 level the amplifications marked a significant increase compared to the level of 
amplifications in PanIN 1 (y;>=0.048). No significant difference was seen in the level of 
deletions when comparing the various histological stages.
Further statistical analysis using one-way ANOVA mean comparisons test showed 
no significant difference in the levels of deletions between various histological stages 
or when each of them was compared to normal ducts from normal specimens. For 
amplifications, the one-way ANOVA mean comparison test showed a significant dif­
ference between groups (;?<0.001) and in particular, between PDAC and the normal 
ducts from normal specimens {p=0.002, 95% CI=6.79-34.06).
2.3.1.10 Chromosome 18
The overall aneuploidy for chromosome 18 in the advanced histological stages (PanIN 
3, PDAC) reached higher levels compared to the overall aneuploidy in the initial stages 
(PanIN 1, PanIN 2) (Fig. 2.19). There was a marked increase between PanIN 2 and 
PanIN 3 stage while the levels in PDAC retained a similar value to PanIN 3. Most 
of the pancreatic ductal cells scored in PanIN 3 and PDAC lesions were aneuploid 
cells (mean 59.12% and 58.17%, respectively). Overall aneuploidy was mainly repre­
sented by deletions in the early stages (PanIN 1) but starting with the PanIN 2 stage the 
amplifications levels increased until in PanIN 3 and PDAC they were at a significantly 
higher level and contributed to aneuploidy in a comparable percentage as the deletions. 
There was a slight positive trend in the levels of deletions between PanIN 1A (mean 
27.73%, range 17.5-48.03%) and PanIN IB (mean 36.75%, range 17.05-51.73%), but 
the trend did not continue in the later stages, displaying a slight decrease in PanIN 2 
(mean 35.80%, range 15.17-55.31%) that continued in PanIN 3 (mean 35.72%, range 
8.57-54.35%) and PDAC (mean 32.30%, range 20.44-42.53%).
Meanwhile, for amplifications, the levels were initially very low in PanIN 1A 
(mean 1.57%, range 0-13.72%) and IB (mean 0.88%, range 0-3.80%), then showed 
a minimum increase in PanIN 2 (mean 2.67%, range 0-48.69%) and then a marked 
increase in PanIN 3 (mean 23.39%, range 0.39-76.62%) remaining at a comparable
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value in PDAC (mean 25.86%, range 1.74-55.24%). The wide range of values for the 
levels of amplifications in PanIN 2, PanIN 3 and PDAC suggested that different cell 
clones drive individual trends in the chromosomal number anomalies seen in chrom o­
some 18. The levels of amplifications seen in all stages carried biological significance 
for the carcinogenesis process especially as reflected in the levels found in PanIN 3 
(mean 23.39%), and PDAC (mean 25.86%).
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Figure 2.19: Overall number of aneuploid cells, cells with deletions and cells with 
amplifications (mean%) displayed by chromosome 18 in progressive histological 
stages; increasing trend towards PDAC for overall aneuploidy and amplifications; * 
indicates stages with statistically significant differences (/?-value<0.05) compared
with preceding stages.
The initial statistical analysis with Student’s paired t-test showed a significant pos­
itive trend of the overall aneuploidy in later stages compared to normal ducts or ear­
lier stages: PanIN 2 vs. normal ducts from PDAC specimens (/?=0.019), PanIN 3 vs. 
normal ducts from normal specimens (/?=0.027) and PanIN 1 (;;>=().0002), PDAC vs. 
normal ducts from normal specimens (p=0.024) and PanIN 1 (p=0.0002). For amplifi­
cations, a significant increase was noted in PanIN 2 and PanIN 3 compared to earlier 
stages: PanIN 2 vs. PanIN 1 (p=0.039), PanIN 3 vs. normal ducts from PDAC speci­
mens (/?=0.006) and vs. PanIN 1 (/?=0.002).
Further statistical analysis using one-way ANOVA mean comparison test showed 
no significant difference in the levels of deletions when comparing the different his­
tological stages in turn or each stage with the others. For amplifications, there was a 
significant difference between histological lesions (/?=0.001) but further detailed anal­
ysis failed to reveal the critical stage where the difference becomes significant.
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2.3.2 Case studies
In order to illustrate the individual patterns of aneuploidy in different specimens we 
selected several specimens which displayed a combination of different histological 
stages relevant for this concept. In those cases the analysis of overall aneuploidy as 
well as chromosomal gains and losses provided insight into how these changes may 
develop in the progression of individual tumours. In the majority of cases, though, one 
or two histological stages distinct from the PDAC tissue were predominant.
Patient 7 This PDAC specimen contained normal ducts, ducts with PanIN 2, PDAC 
and a lymph node metastasis. The levels of overall aneuploidy across all chromoso­
mal probes (1, 6, 9 and 18) increased from a baseline value in the normal ducts to a 
maximal value in the areas with PDAC and metastasis (Fig. 2.20). Chromosome 9 dis­
played a marked difference between the levels in normal ducts and those in PDAC and 
metastasis (31.58%, 34.90% respectively). A similar trend was seen for chromosome 
18: 13.44% and 42.80% difference between normal ducts and PDAC and metastasis, 
respectively. Meanwhile, for chromosome 1 and 6, the values generated a slight up­
ward trend towards the advanced stages (14.50%, 5.47% difference between normal 
and PDAC ducts, respectively).
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Figure 2.20: Different histological stages from the same PDAC specimen (normal, 
PanIN 2, PDAC and lymph node metastasis) display various levels of overall
aneuploidy.
Deletions accounted for the main percentage of the overall aneuploidy in all histo­
logical stages and for all chromosomal probes investigated. Meanwhile, amplifications 
marked the carcinogenesis process with low values compared to deletions but with in­
creased molecular significance. The levels increased from zero in the normal ducts to 
4.26% for chromosome 1, 1.94% for chromosome 6, 0.77% for chromosome 9 and 
0.27% for chromosome 18 in the metastatic tissue (Fig. 2.21).
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Figure 2.21: Different histological stages from the same PDAC specimen (normal, 
PanIN 2, PDAC and lymph node metastasis) display various levels of amplifications.
The trends in chromosomal gains and losses seen in this specimen highlighted the 
role of amplifications and how different chromosomes displayed individual aneuploidy 
variations along the carcinogenesis process.
Patient 16 This PDAC specimen contained pancreatic ducts with normal tissue, 
PanIN IB and PanIN 3. The levels of overall aneuploidy and amplifications are il­
lustrated in Fig. 2.22 Chromosome 1 and 6 followed a marked positive trend in overall 
aneuploidy between normal ducts and PanIN 3 (28.78% and 48.52% difference, re­
spectively). Meanwhile, chromosome 9 and 18 appeared to follow a counterintuitive 
trend, with decreasing levels in PanIN 3 compared to PanIN IB (-16.45% , -7 .81%  
difference respectively). This illustrated that carcinogenesis is a highly diverse process 
that generates chromosomal abnormalities in a random fashion.
A marked increase was detected when comparing the level o f amplifications for 
chromosome 1 and 18 in PanIN 1B and PanIN 3 (32.16% and 9.92% difference, respec­
tively). Meanwhile, no chromosome 6 amplifications could be confidently identified 
in any histological entity from this particular specimen. Interestingly, chromosome 
9 showed virtually no increase in the level of amplifications between PanIN IB and 
PanIN 3 (0.59% difference) (Fig. 2.23).
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Figure 2.22: Different histological stages from the same PDAC specimen (normal, 
PanIN IB and PanIN 3) display various levels of overall aneuploidy.
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Figure 2.23: Different histological stages from the same PDAC specimen (normal, 
PanIN 1B and PanIN 3) display various levels of amplifications.
Patient 19 In another PDAC case included in this case series the trends in the levels 
of aneuploidy in different histological stages showed that the overall aneuploidy in the 
early stages was higher than that documented in the late stages. The scoring for this 
PDAC specimen was done on two normal pancreatic ducts, two PanIN 1B lesions, one 
PanIN 2 and one PanIN 3.
The average aneuploidy across all chromosome probes in the normal ducts was 
52.45%, 58.98% in the PanIN IB lesions, while in the PanIN 2 and PanIN 3 it reached 
55.41% and 46.89%, respectively. The overall trend followed a negative curve towards 
the advanced pre-malignant stage (Fig. 2.24).
Most of the overall aneuploidy was represented by deletions, while the amplifica­
tions maintained a low profile across the chromosome probes. Chromosomes 6 and
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Figure 2.24: Different histological stages from the same PDAC specimen (normal, 
PanIN IB, PanIN 2 and PanIN 3) display various levels of overall aneuploidy.
9 showed stationary levels across all histological stages in this specimen (range 0- 
1.38%, range 0-2.16% respectively) with the highest values seen in the normal ducts, 
while the PanIN 3 lesion displayed minimal scores (0.14%, 0.92% respectively). There 
was a different trend in the levels of amplifications for chromosome I: a high value 
in the normal ducts (7.27%), a decrease in PanIN IB (6.61% difference) sustained in 
PanIN 2 (4.68% difference compared to normal) followed by an increase in PanIN 3 
(4.15% difference compared to PanIN 2). For chromosome 18, the highest score was 
found in the PanIN 2 (7.53%), while the score in PanIN 3 was lower (5.74%) and only 
0.89% in PanIN 1B and 0% in the normal ducts (Fig. 2.25).
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Figure 2.25: Different histological stages from the same PDAC specimen (normal, 
PanIN IB, PanIN 2 and PanIN 3) display various levels of amplifications.
The heterogeneity in the chromosomal changes in this specimen as well as the 
reverse trend in overall aneuploidy suggested that in some malignant clones the initial 
expansion of aneuploidy is a self-limiting process as the carcinogenesis advances.
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2.4 Discussion
2.4.1 Average aneuploidy
In general, the level of aneuploidy in a tumour is closely related to type, stage and 
histological grade. Individual patterns in different cases with the same type of tumour 
confirm that aneuploidy develops in relation to individual genetic guidelines and path­
ways. Thus, it can be considered a trademark process in evaluating individual stages 
in carcinogenesis.
The scoring for aneuploidy in normal pancreatic ducts from PDAC specimens re­
vealed a high level of aneuploidy (range 18.42-74.66%) that appeared contradictory 
as the ducts were selected from an area away from the main tumour and macroscop- 
ically classified as not involved in the tumoural process. Several normal pancreatic 
ducts from normal pancreatic specimens (multiple congenital cysts, lympho-epithelial 
cyst, peritoneal pseudocyst) were included to support the evaluation of the background 
aneuploidy level. The limitations in this approach were that pancreatic surgery for 
non-cancerous diseases is very rare and even then it is likely that the disease pro­
cess involved precludes the confident identification of normal ducts. The normal ducts 
included were selected from specimens with benign disease with no chromosomal 
changes.
The aneuploidy scoring in the normal ducts from the normal specimens revealed 
comparable results (range 25.28-59.40%) to the scoring in the normal ducts from the 
PDAC specimens, prompting the conclusion that the high level of background aneu­
ploidy in the PDAC specimens is not related entirely to the proximity to the tumour. 
Potential alternate explanations relate to sectioning bias (when the level of sectioning 
cuts accross the nuclei and causes the chromosome pair to be fragmented, generating 
a false low chromosome count), scoring bias (tissue architecture in the normal ducts 
allows good visualisation of the nuclei with significantly less overlapping compared 
to advanced stages, thus leading to more aneuploid nuclei being included in the scor­
ing) or tissue bias (pancreatic tissue displaying a relatively high level of aneuploidy 
unrelated to a cancerous process).
The vast majority of the available studies focused on chromosomal aberrations used 
region-specific FISH probes to uncover amplifications and/or deletions relevant to the 
genes located on the respective region. For example, Ghadimi et al. 1999 used FISH 
to validate their findings revealed by comparative genomic hybridization (CGH) and 
spectral karyotyping (SKY) on pancreatic cancer cell lines: consistent chromosomal 
gains for chromosomes lq, 5, 7, 8, 10, 11, 12q, 16p, 18ql 1-12, and 20 and losses 
for chromosomes 9p, 18q, and Xp (Gambini BM et al., 1999). Another study using 
CGH and SKY on pancreatic cancer lines reported frequent chromosomal gains for 
chromosomes 3q, 8q, 1 lq, 17q and 20 and losses for chromosomes 6q, 8p, 17p and 18
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(Griffin CA et al., 2007).
Our study showed that, as expected, the average level of amplifications seen across 
all chromosome probes remains low in the early premalignant stages (PanIN 1, PanIN 
2) but increases significantly in the PanIN 3 and PDAC level. Also, the range of values 
in the advanced stages is wider indicating that different tumour clones display individ­
ual patterns of aneuploidy best reflected in the levels of amplifications.
The average level of deletions in the specimens included was more difficult to 
interpret accurately mainly because of sectioning bias but it is acknowledged that, 
generically, they play a contributing role to carcinogenesis.
2.4.2 Amplifications
The most significant part of the results was reflected by the levels of amplifications. All 
chromosome probes included in this study displayed aneuploidy in the form of ampli­
fications, but chromosome 1 showed the highest levels in PDAC (29.23%). For PanIN 
3, the highest level was seen in chromosome 18 (23.39%), while chromosome 1 dis­
played a similar value (22.39%). In the other premalignant stages the levels remained 
low for all chromosome probes. Also, each chromosome displayed amplifications in 
an increasing pattern towards the last stages of carcinogenesis.
Most of the cells displaying amplifications showed more than three chromosomal 
copies typically for both probes used for hybridization. Some areas of the pancreatic 
ducts with PanIN 2 or PanIN 3 were particularly dense in aneuploid cells with ampli­
fications suggesting that those cells derived from the same clone in the carcinogenesis 
process.
The areas with overlapping of the nuclei have been excluded to avoid overscoring 
for amplifications, so potentially the true levels in the tissue could be higher than the 
levels documented in the study.
Studies have shown that FISH analysis on ERCP brushings from the pancreatobil- 
iary system can twice the sensitivity of a positive diagnosis for malignancy compared 
to positive routine cytology alone by detecting chromosomal gains (Kipp BR et al., 
2004, Moreno Luna LE at al., 2006).
2.4.3 Chromosome 1
Chromosome 1 is the largest human chromosome, representing approximately 8% of 
the total cellular DNA (US NLM, 2012).
In our study, chromosome 1 displayed a high level of amplifications in the PanIN 3 
stage of carcinogenesis. The deletions proportion increased towards the last stages and, 
despite the bias involved in their analysis, they suggest an accumulation of anomalies 
as the carcinogenesis advances. PanIN 3 and PDAC display levels of amplifications
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significantly higher than the earlier stages which may suggest that in advanced stages 
chromosome 1 has a significant role in defining the tumour genotype.
Hilgers et al. identified loss of heterozygosity (LOH) on the chromosomal arm lp 
in 50% of pancreatic cancers evaluated, suggesting the presence of a tumour suppresor 
gene on that locus (Hilgers et al., 1999).
2.4.4 Chromosome 6
Between 5.5% and 6% of total cellular DNA is found on chromosome 6. Several 
oncogenes have been located on the short arm (6p) which is frequently duplicated in 
cancers (US NLM, 2011).
The levels of overall aneuploidy in chromosome 6 follow a different trend com­
pared to chromosome 1, displaying a stable relatively high value in all histological 
stages. The levels of deletions constitute the main chromosome abnormality. This 
suggests that deletions in chromosome 6 numbers are a significant molecular event 
in pancreatic carcinogenesis, despite tissue sectioning bias. The levels of amplifica­
tions in chromosome 6 are overall low in all specimens, only significantly increasing 
in PDAC compared to the other histological stages. Advanced statistical analysis con­
firmed a significant increase in deletions in PanIN 2 and PDAC compared to normal 
specimens.
2.4.5 Chromosome 9
Chromosome 9 represents approximately 4.5% of the total cellular DNA (US NLM, 
2012).
The chromosome 9 aneuploidy levels are mainly represented by deletions, similar 
to the pattern seen for chromosome 6, but at a lower value. The level of amplifications 
for chromosome 9 remains low in all premalignant stages except for PanIN 2 where it 
shows a minimal increase. There is a marked increase in amplifications corresponding 
to the PDAC stage which highlights the significance of the chromosomal gains in this 
stage when compared with all the other stages. Amplifications appear to be the main 
chromosome number anomaly affecting chromosome 9 in pancreatic carcinogenesis in 
the specimens included in this study.
2.4.6 Chromosome 18
Chromosome 18 represents 2.5% of the total cellular DNA and carries the tumour 
suppressor gene SMAD4 on locus 18q21.1 (US NLM, 2012).
Chromosome 18 displays significantly higher levels of overall aneuploidy in PanIN 
3 and PDAC compared to the early stages (PanIN 1, PanIN 2). The marked increase in
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the levels of amplifications in PanIN 3 demonstrates the central role that amplifications 
play in the abnormal profile of chromosome 18 in pancreatic carcinogenesis in the 
specimens included in this study. There is a wide range of values for amplifications 
displayed in PanIN 2, PanIN 3 and PDAC suggesting that different cell clones drive 
individual trends in the chromosomal number anomalies in this case. Also, PanIN 2 
appears to represent a critical stage in the trend of anomalies in chromosome 18 but 
that was not confirmed on a one-way ANOVA mean comparison test.
A study using comparative genomic hybridization (CGH) to screen 33 pancreatic 
ductal adenocarcinomas for genomic alterations found that chromosome 18 was the 
chromosome altered preferentially. The tumours investigated in the study displayed 
frequent chromosomal losses involving 18q, lOp, 8p, 13q (Schlege C, 2000). Similar 
findings regarding chromosome 18 were reported in an earlier attempt to establish 
the most consistent chromosomal abnormalities in PDAC, using fluorescence in situ 
hybridization as the design method (Griffin C et al., 1995). This is in contrast with 
the pattern we found for chromosome 18: amplifications were predominant in the 
specimens with PDAC.
Meanwhile, a study including 20 primary pancreatic non-endocrine tumours and 9 
metastases reported a different set of results, using chromosome banding after short­
term culture. They found that the main karyotypic imbalances were chromosome 
losses in 18, Y and 21 and gains of 7, 2, and 20, partial or whole-arm losses of lp, 
3p, 6q, 8p, 9p, 15q, 17p, 18q, 19p, and 20p, and partial or whole-arm gains of lq, 3q, 
5p, 6p, 7q, 8q, 1 lq, 12p, 17q, 19q, and 20q (Gorunova L, 1998).
One small study aiming to test the utility of FISH in evaluating chromosomal alter­
ations in PDAC showed losses for chromosome 8, 17 (four out of 10 cases for both), 20 
(three out of 10 cases) and 18 (two out of 10 cases) alongside gains for chromosomes 
7 and 18 in one tumour (Adsay N et al., 1999).
2.4.7 Case studies
PDAC specimens with different histological stages were selected and the levels of 
overall aneuploidy and amplifications were analysed by simple comparison. In one 
specimen, the trends followed a predictive upward curve from normal ducts to PanIN
2, PDAC and lymph node metastasis. For amplifications this carries a marked signif­
icance at molecular level as it highlights how carcinogenesis disrupts normal cellular 
division resulting in tumour growth and metastasis. In another specimen, the trends 
followed the expected increase only for chromosome 1 and 6 from PanIN IB to PanIN
3. The levels of overall aneuploidy seen in chromosome 9 and 18 followed a down­
ward trend between the same histological stages. Amplifications in the same specimen 
increased towards PanIN 3 only for chromosome 1 and 18, while the trend was sta­
tionary for chromosome 9 and a zero value was recorded for chromosome 6 across all
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histological stages.
The trends of aneuploidy and chromosomal gains, in particular, seen in different 
PDAC specimens illustrate the random pattern of chromosomal abnormalities in vari­
ous histological stages as the carcinogenesis progresses in the specimens included in 
this study.
Different tumour genomes involve different types of genetic instability. The link 
between chromosomal aberrations and prognosis has been shown for a variety of tu­
mours like prostate cancer (Paris P.L. et al., 2004), breast cancer (Callagy G et al., 
2005), gastric cancer (Weiss MM et al., 2004) and lymphoma (Martinez-Climent JA et 
al., 2003, Rubio-Moscado F et al., 2005). This area of research needs expanding with 
studies to validate the observational statistical results.
2.4.8 Survival analysis
Overall, the survival of the patients included in this study was 12 months on average, 
ranging from 3 months to 18 months, which is consistent with the data from the liter­
ature (NCI, 2009). There was a significant increase in survival where the tumour size 
was less than 4 cm (p=0.041) but the sample size was relatively small. For the same 
reason, there were limitations towards a more in depth analysis including aneuploidy 
levels. However, a noteworthy observation was made about an apparent correlation 
between relatively high levels of average aneuploidy in tumour areas and decreased 
survival. In one case with 64.04% average aneuploidy across all the investigated chro­
mosomes the survival was only 7 months. Similarly, 57.81% average aneuploidy was 
associated with a survival of 6 months, 52.72% with 9 months, while 48.72% average 
aneuploidy was noted in a case with 20 months survival. All the described cases re­
ceived postoperative chemotherapy and the tumour size ranged between 4 and 6 cm, 
which is an important factor for survival as mentioned previously. The average lev­
els of amplifications seen in the actual tumour areas did not correlate significantly with 
survival but it was noted that the cases with a high level (10.73%, 23.33% and 27.66%) 
had a relatively shorter survival (9, 7 and 6 months, respectively) compared to a case 
with 1.07% average amplifications which survived for 13 months.
In the cases displaying PanIN 3 lesions the survival analysis was equally difficult 
due to the small sample size and confounding factors like tumour size, local invasion 
and postoperative chemoradiotherapy. Nevertheless, it is worth noting that a high level 
of average aneuploidy (57.41%) was associated with a 6 months survival while a rel­
atively lower level of aneuploidy (38.04%) was associated with a 10 months survival. 
The same observation does not apply to the average levels of amplifications in PanIN 
3 where in one case a level of 37.87% was associated with a 6 months survival while a 
level of 3.58% was seen in a case with 10 months survival and 2.14% in a case with 3 
months survival. Overall, the levels of aneuploidy appear to have a link with survival
but a more detailed analysis in a larger sample size would be needed to confirm that.
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2.5 Conclusion
The levels of aneuploidy found in the specimens included in this study pertinent to 
chromosomes 1, 6, 9 and 18 reinforced the fact that aneuploidy is a significant event 
in pancreatic carcinogenesis. The significant increase in the PanIN 3 premalignant 
stage indicates that this stage accumulates the genetic anomalies inexorably leading 
to the fully established stage of adenocarcinoma. The amplifications are the most 
relevant anomaly and mainly chromosomes 1, 9 and 18 were affected by this type of 
missegregation while chromosome 6 displayed predominantly deletions.
Further investigations into a larger panel of chromosomes and with extension to 
other parameters (proteomics, metabolics) could add to the already established grounds 
for personalized genetic therapy.
The recognized causes for aneuploidy are: chromosomal instability and aneugens 
(exogens that cause aneuploidy). In pancreatic carcinogenesis the chromosomal insta­
bility appears to have the main role in aneuploidy while there is no direct evidence that 
aneugens are involved. The current study confirms this hypothesis which leads to the 
question what causes the instability and whether the mitotic checkpoint remains intact 
during carcinogenesis. The next chapter was designed as an attempt to investigate the 
Mad2 and BubRl mitotic checkpoint proteins in the PanIN premalignant lesions.
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Chapter 3 
Mad2 and BubRl
3.1 Introduction
Mad2 and BubRl are two important proteins involved in controlling the cell cycle as 
part of the spindle assembly checkpoint. The genes that control these proteins are part 
of the genetic pathways involved in controlling the cell cycle and so genetic defects 
at this level can lead to chromosomal instability and carcinogenesis (Jallepalli P et al., 
2001). Mad2 mutations have been shown in breast and bladder cancer (Percy et al., 
2000, Hernando et al., 2001) while BubRl mutations are associated with colon cancer 
(Weaver BA et al., 2006, Cahill DP et al., 1998).
Immunohistochemistry (IHC) is a method of investigating the presence and loca­
tion of proteins in tissue sections. It is based on the antibody-antigen reaction. This re­
action can be visualized using chromogenic or fluorescent detection. The chromogenic 
detection uses an enzyme conjugated to the antibody which produces a colour precip­
itate at the site of the protein. The fluorescent detection method uses a fluorophore 
which is conjugated to the antibody and can be visualized using fluorescence mi­
croscopy (Buchwalow IB et al., 2010). As the antibody is highly specific for the target 
protein, it represents a valid method for detecting the protein of interest. Thus, it is 
widely used in diagnostic, prognostic and research fields. It is relevant in diagnosing 
tumours of unknown origin, in investigating prognostic markers in cancer by identify­
ing relevant enzymes, tumour-specific antigens, tumour suppressor genes, oncogenes 
and tumour proliferation markers and in predicting the response to therapy in breast 
and prostate cancer. It is also used to confirm infectious agent in tissue with antimicro­
bial antibodies. It has a role in investigating neurodegenerative disorders, brain trauma 
and muscle disease. In genetics it can be used to establish the function of specific 
proteic gene products involved in various genetic pathways (Duraiyan J et al., 2012).
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3.2 Materials and method
3.2.1 Sample characteristics
A panel of 20 normal ducts, 18 ducts with PanIN 1, 6 ducts with PanIN 2,7 ducts with 
PanIN 3, 4 ducts with PDAC and one lymph node metastasis was selected out of the 
sample used to score aneuploidy.
The sample was formed by 15 patients, male:female ratio 1:1.5, average age 70 
years.
The inclusion criteria involved sectioning feasibility (further sectioning was not 
possible in the specimens where the ducts with PanlNs were peripheral), the presence 
of progressive histological stages in the same specimen, relatively high or low levels of 
aneuploidy. The exclusion criteria involved inability to obtain further sections. Also, 
the time limitations for this pilot study did not allow the inclusion of all available 
specimens or of other relevant proteins.
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3.2.2 Optimization
The antibodies used were the MAD2L1 Rabbit anti-Human Polyclonal (aa3-13) an­
tibody (lmg/ml, Lifespan Biosciences) for Mad2 and BUBlB/BubRl Rabbit anti- 
Human Polyclonal Antibody ( 0.5mg/ml Lifespan Biosciences) for BubRl. The Mad2 
antibody was optimized using human cerebral tissue while the BubRl antibody was 
optimized using human endometrial tissue, as per manufacturer instructions. This was 
performed in the Graduate Entry Postgraduate Laboratory, Singleton Hospital ABMU 
Health Board. The Ventana automated immunohistochemistry protocol was used (Ven- 
tana Medical Systems, Tucson, AZ). All the steps in the optimization process as well as 
the supervision of the automated method was done by the senior staff in the Pathology 
Laboratory as per laboratory protocol.
Several readjustments were needed to ensure adequate staining as assessed by two 
independent reviewers.
An optimal dilution of 1:200 was obtained for Mad2 and 1:100 for BubRl which 
enabled adequate staining on PDAC tissue.
The formalin-fixed paraffin embedded (FFPE) archival tissue sections from tissue 
blocks obtained after elective surgical resection for malignant or benign pancreatic 
disease were stored in the Histopathology Department, Morriston Hospital, ABMU 
Health Board Swansea. Immunostaining was performed on close serial sections cut 
from the same paraffin block used for the aneuploidy study so that the same duct could 
be analysed.
The 4 /im thick FFPE sections were kept at 37°C for 1 hour prior to the staining 
treatment.
The selected sections were then introduced in an automated system used for im­
munohistochemistry (Ventana Medical Systems, Tucson, AZ). The protocol used an 
indirect biotin-avidin system coupled to an enzyme product to allow visualization of 
the bound antibody. The detection kit used secondary antibodies to locate the bound 
primary antibody and was followed by the binding of an avidin enzyme conjugate to the 
biotin. The complex could then be visualized using a precipitating enzyme generated 
product. All the reagents, antibodies and stains were introduced in the corresponding 
slots in the carousel of the automated system. The slides to be analyzed were labeled 
with slide barcode labels generated by the automated protocol and introduced in their 
respective carousel. The automated system then ran the process to a set automated pro­
tocol. At the end of each workday an instrument cleaning procedure was performed. 
Biannual calibration was ensured. A negative control was run from each tissue block 
by excluding the application of the primary antibody.
81
3.3 Results
Each set of sections was accompanied by a hematoxylin and eosin stained section to 
allow identification of the relevant histopathological structures. This was compared 
with the sections used for IHC and thus the areas of interest were marked (Fig 3.1 -
The scoring protocol included a score for the intensity of the staining and a score for 
the distribution of the staining. The Mad2 antibody produced predominantly nuclear 
staining, whereas the BubRl antibody showed both cytoplasmic and nuclear staining. 
This has been shown in the literature in cases of PDAC and it seems to be related to the 
altered permeability of the nuclear membrane as a result of the carcinogenesis process 
(Burum-Auensen et al., 2007).
The scoring was performed for nuclear staining only and involved a score of 0 to 3 
as per following:
• For intensity: • For distribution:
The intensity and distribution of staining for the two different proteins varied be­
tween different histological stages for the same protein and also between the two pro­
teins in the same specimen (Fig. 3.3).
The final score for each specimen was obtained by multiplying the intensity score 
by the distribution score.
3.2).
-  0 = no staining
-  1 = weak staining
-  2 = moderate staining
-  3 = strong staining
-  0 = no cells stained
-  1 = less that 30% of cells stained
-  2 = 30-60% cells stained
-  3 = over 60% cells stained
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PanIN 3 ducts
i  w* >. r
(a) H aem atoxylin -eosin  (H E) section  x lO  show ing  
the m ultilayered ductal ce lls  with som e desquam a­
tion from the top layer and m ucin accum ulation at 
the apical pole.
nuclei
PanIN 3 duct
'anlN3<d,uct
- \ j  \ 
* nuclei
(b) FISH section  x60  seen  w ith DA PI filter show ­
ing a fragment o f  the duct w ith CEP 9 green signals, 
CEP 18 orange sign a ls , DAPI blue ce lls  nuclei and 
non-specific  cytop lasm ic uptake.
; ^  Intranuclear^ 
Staining ^
'intranuc 
staining
(c) Photom icrograph o f  the duct after im m unostain- 
ing using M ad2 antibody with brown antibody pre­
dom inantly intranuclear staining and blue nucleo­
plasm  staining.
Figure 3.1: Tissue section with PanIN 3; PanIN 3 ducts highlighted on the HE
section; the chromosomal probes CEP 9 and CEP 18 highlighted on the FISH section;
the Mad2 score 6 staining highlighted on the IHC section.
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(a) H aem atoxylin-eosin  (H E) section  x 10 show ing  
the duct with areas o f  m ultilayered cells  with m ucin  
accum ulation at the apical pole
PanIN 1B duct
nuclei CEP 1
CEP 6
(b) FISH section  xGO seen with DAPI filter show ­
ing a fragment o f  the duct w ith CEP 6 green signals, 
CEP l orange signals, DAPI blue ce lls  nuclei and 
non-specific cytoplasm ic uptake in the stromal layer
^PanlN 1 
f  ' .  duct
^intranuclear" 
% t^aioing 1
(c) Photom icrograph o f  the duct after im m unostain- 
ing using B ubR l antibody with brown antibody in­
tranuclear and cytoplasm ic staining and blue nucleo­
plasm  staining.
Figure 3.2: Tissue section with PanIN IB; PanIN IB duct highlighted on the HE
section; the chromosomal probes CEP 1 and CEP 6 highlighted on the FISH section;
the BubRl score 4 staining highlighted on the IHC section.
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(a) BubRl
(b) M ad2
Figure 3.3: Photomicrograph x40 with immunostaining for BubRl (score 2) and 
Mad2 (score 6), respectively, in the same specimen displaying pancreatic ductal
adenocarcinoma
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3.3.1 Statistical analysis
For analysis, the final scoring results were divided into overall and average protein 
levels.
They were then analysed using IBM SPSS Statistics version 2011. A Student 
paired t-test was used to compare the results for groups of two different histological 
stages and a Linear Mixed-Effect model was used to determine potential correlations 
with the aneuploidy data as well as specimen characteristics. Significance was at­
tributed to a />value less than 0.05. Several case studies were included to illustrate 
individual patterns in different tumours.
3.3.1.1 Protein levels (cohort and average values)
The detailed plotting of all values for the Mad2 protein levels in different histological 
stages followed a non-linear trend, similar to the average values included further on 
in this chapter. A median score of 6.00 was seen in all histological stages. The levels 
in normal ducts and in the areas with PDAC were similar, with most of the values 
positively skewed compared to the median. The levels found in PanIN 1 and PanIN 2 
were below the median while PanIN 3 displayed values very different compared to the 
median (Fig. 3.4).
Mad2 protein levels
G>
k .Oo
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,1 4 .00“
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NormayrYormal P'iormal Rants! 1 PanIN 3 PDAC
Histology
Figure 3.4: Box plot illustrating the levels of the mitotic checkpoint protein Mad2 in 
progressive histological stages scored by nuclear immunostaining; the median is 
represented by the thick horizontal line; outlier values are marked by O and ★
respectively
The detailed plotting o f the values obtained for BubRl showed a different trend 
compared to the values for Mad2 (Fig. 3.5). The median values for each histological
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stage were variable and a score of zero (no staining seen), was found in some samples 
in all premalignant stages (normal, PanIN 1, PanIN 2 and PanIN 3). Noticeably, the 
values seen in PDAC were higher than all the other stages, as individual values as well 
as a median value (median=4.00, compared to median=3.00 in normal ducts and PanIN 
3 and median=2.00 in PanIN 1 and PanIN 2). Also, most histological stages displayed 
outlier values on either side of the median.
BubRl protein levels
9 .0 0 -
6.00-O
k _
8  4 .0 0 -  
3.00"
0c
■§ 2 .00-
CQ
1. 00-  
.00-
Nomal/norrral Normal PanIN 1 PanIN 2 PanIN 3 PDAC
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Figure 3.5: Box plot illustrating the levels of the mitotic checkpoint protein BubRl in
progressive histological stages scored by nuclear immunostaining; the median is 
represented by the thick horizontal line; outlier values are marked by O
For a basic comparison of the scores in different histopathological stages, the aver­
age score for each histopathological stage (i.e. normal ducts, PanIN l , PanIN 2, PanIN 
3 and PDAC) was calculated for Mad2 and BubRl and the results included in a bar 
graph (Fig. 3.6).
The average score for Mad2 across all histopathological stages showed disorga­
nized variability. The levels in the normal ducts (average score 6.473) nearly reached 
the maximum average score across all stages (average maximum score 6.75, in PDAC).
The average score in PanIN 1 (A and B) showed a negative trend compared to 
the average score in the normal ducts (14.18% difference) but was higher than the 
score in PanIN 2 (16% difference). The average score in PanIN 3 displayed a 24.03% 
increase compared to PanIN 2 and a 9.56% increase compared to PanIN 1. Similarly, 
the average score in PDAC reached the maximum of all scores and was higher than the 
average score in PanIN 1 (17.69% increase) and PanIN 2 (30.86% increase), but was 
still similar to the score seen in normal tissue. No statistically significant difference 
was found between the scores in different histological stages.
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Figure 3.6: The average levels of proteins Mad2 and BubRl scored by nuclear 
immunostaining in progressive histological stages
The average scores associated with BubRl varied between different histological 
stages. The average score seen in the normal ducts was 3.2 and 2.44 in the ducts with 
PanIN 1 (23.61% difference). An increase was seen in PanIN 2 compared to PanIN 1 
(38.88% difference) and the normal ducts (20% difference). Then the average scores 
registered a slight decrease in PanIN 3 compared to PanIN 2 (17.85% difference) but 
then increased significantly in PDAC compared to the normal ducts (/;>=0.050) and 
PanIN 1 (p=0.007).
The display o f the levels of both proteins in relation to histological stages showed 
more distinctly the differences between their trends (Fig. 3.7).
Protein levels
BubRl
N o r m a l  d u c t s  P a n I N  1 P a n I N  2 P a n I N  3  PDAC
Histology
Mad2
Figure 3.7: The combined levels of Mad2 and BubRl in all the histological stages
Thus, in the normal ducts, in the ducts with PanIN 3 and in the areas with PDAC, 
the levels of Mad2 and BubRl generated a trend that is almost the mirror image of 
each other. In the ducts with PanIN 1 and the ducts with PanIN 2 the trend was similar
between the two proteins. Overall, the scores for BubRl were lower than the scores 
for Mad2 in all premalignant stages, while in PDAC they showed disparate trends.
A total of 18 specimens with ducts classed as PanIN 1 (A and B) which displayed 
a wide range of aneuploidy were selected in order to investigate any observational 
trend patterns in the IHC scores related to different extremes of aneuploidy levels. 9 
specimens displayed a relatively low level of average overall aneuploidy across chro­
mosomes 1, 6, 9 and 18 (up to 39% average overall aneuploidy) while the remaining 9 
displayed a relatively high level (above 39% average overall aneuploidy).
The corresponding scores for Mad2 and BubRl were plotted against the average 
overall aneuploidy levels to investigate whether there is any similarity in their trends 
(Fig. 3.8). This showed that in both groups the levels of Mad2 and BubRl followed 
individual trends, not consistently mirrored by the average aneuploidy. This could be 
generated by the fact that the average aneuploidy across all chromosomes included in 
the study blends together highly different individual trends in chromosomal anomalies 
and that the levels of M ad2 and BubRl followed a different trend.
Protein levels and average aneuploidy in PanIN 1
10 7 0
M a d 2
6 0 s c o r e
5 0  >- 
4 0  -§.
BubRl
s c o r e
a v e r a g e
a n e u p l o i d y3 0
20XZ
PanIN  1 w i t h  > 3 9 %  
a v e r a g e  a n e u p l o i d y
Pan IN  1 w i t h  < 3 9 %  
a v e r a g e  a n e u p l o i d y
Figure 3.8: The trends in the immunohistochemistry scores for Mad2 and BubRl 
(values on the primary vertical axis) and in the average overall aneuploidy 
(percentages on the secondary vertical axis) in the specimens with PanIN 1 in 
individual patients with relatively low levels of average overall aneuploidy (<39% , to 
the left of the plot area) and in the specimens with PanIN 1 with relatively high levels 
of average overall aneuploidy (^39% , to the right of the plot area)
In the ducts with PanIN 1 the average aneuploidy was represented by deletions as 
the level of amplifications was on average much lower (0-3.21%) and so the correla­
tions demonstrated earlier were not reflected in this particular set of data.
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3.3.1.2 Correlations
An analysis was conducted to study the interaction between the levels of proteins 
(Mad2, BubRl) and general patient data, specimen level data and chromosome data. 
The patient level data consisted of background characteristics such as patient sex, age 
and tumour size. The specimen level data included a classification of histology, while 
the chromosome data contained measurements of aneuploidy, amplification and dele­
tion levels for chromosomes 1, 6, 9 and 18.
As a consequence of the complex interactions between these variables and the un­
balanced and hierarchical nature of the data set it was felt that simple correlations 
would not provide a robust tool for making these measurements. In place of this Linear 
Mixed-Effect models (LMM) were fitted in SPSS. LMMs are comparison models used 
to compare data from different categories with large a number of independent variable. 
Among the independent variables only the amplification data failed a Kolmogorov- 
Smimov test of normality and was therefore log transformed in order to qualify for 
inclusion. The key dependent variables representing the protein levels (Mad2, BubRl) 
failed a Kolmogorov-Smimov test, and could not be transformed. However, this failure 
appeared to be as a result of their discrete structure and as they exhibited neither strong 
asymmetry nor long tails it was felt that the method would be sufficiently robust.
The first stage of the analysis was to identify which of the background variables 
correlated with the protein and chromosome levels so that their effect could be in­
cluded in any tests of correlation. A LMM was fitted in each case, with the optimal 
model chosen using AIC/BIC criteria rather than the p -values of the individual terms. 
Table 3.2 shows the chosen parameters included in the optimal models for each vari­
able. These are potential confounders and should be included in any test of correlation 
to compensate for their impact. Only one of the two associations involving protein lev­
els was significant, with the groups of PanIN 3 and PDAC associated with significantly 
reduced Mad2 levels (/?=0.025).
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Table 3.2: The parameters included in the optimal models for each variable in the
LMM model
Variable Histology Sex Age Tumour Size
Mad2 1 — — —
BubRl — — — 1
Ploidl — 1 — —
Ploid6 — — — —
Ploid9 1 — 1 —
Ploidl 8 1 — — —
Ampl 1 — — —
Amp6 1 1 1 —
Amp9 1 — — —
Amp 18 — — — —
Dell 1 1 — 1
Del6 — — — —
Del9 — — 1 —
Del 18 — — — 1
A LMM was then built to measure the residual correlation between protein levels 
and all of the chromosome markers in turn, after allowing for the effects of all corre­
lates of either variable. The statistically significant associations are shown in Table 3.3.
Given the large number of tests we conducted there is a serious danger of false pos­
itive results due to multiple testing. None of these results would be likely to survive 
a conservative correction for multiple testing (such as Bonferroni), although it is ar­
guable whether such a correction is necessary, or even appropriate. As a consequence 
of these points and of the distribution of certain key variables we should be cautious in 
our interpretation of the findings.
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Table 3.3: The statistically significant associations obtained from the LMM model
Dependent
Variable
Independent
Variable
p -value Estimate (95% Cl) Other variables 
included in model
Mad2 Ampl 0.011* -0.83 [-1.45,-0.20] Histology
BubRl Ampl 0.058 0.47 [-0.02,0.96] Histology, 
Tumour size
BubRl Amp6 0.008** 1.80 [0.55,3.05] Histology, Sex, 
Age, Tumour size
BubRl Dell 0.024* -0.06 [-0.12,-0.01] Histology, Sex, 
Tumour Size
*p < 0.05 ; **p < 0.01
3.3.2 Case studies
We selected several specimens with a variety of progressive histological stages in or­
der to provide insight into the characteristics of individual tumours and also into the 
relevant changes at chromosomal and mitotic checkpoint protein levels.
For the purpose of illustrating this, examples were included in this analysis, similar 
to the case studies in the chapter on aneuploidy.
The first case study is based on a specimen that displayed normal ducts, ducts 
with PanIN IB, ducts with PanIN 2 and ducts with PanIN 3. The levels of amplifi­
cations, deletions and overall aneuploidy were scored as described in the aneuploidy 
chapter and then the levels of the Mad2 and BubRl proteins were scored by immuno- 
histochemistry. In this particular case, the values for the parameters described do not 
follow intuitive or correlated trends (Fig. 3.9).
The average percentages for overall aneuploidy and deletions across chromosomes 
1, 6, 9 and 18 displayed a slight negative curve starting with PanIN IB and through 
to PanIN 3 while the average percentages for amplifications described a slight positive 
curve in the same histological stages. These trends were not consistently reflected by 
the trends for the levels of Mad 2 and BubRl: BubRl showed no uptake in the ducts 
with PanIN IB, PanIN 2 or PanIN 3 (but generated a score of 1 in the normal ducts, 
hence excluding technical bias) while Mad2 reflected the overall trends seen in the 
average Mad2 levels: high score in the normal ducts, decreasing then in the PanIN IB, 
PanIN 2 and increasing sharply in PanIN 3.
The second case study involved a specimen with normal ducts, ducts with PanIN 2, 
areas with PDAC and an adjacent lymph node metastasis. The trends for the average
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Figure 3.9: The trends for average aneuploidy, average amplifications and average 
deletions (percentages on the primary Y axis) and for the immunostaining scores for 
the Mad2 and BubRl protein levels (values on the secondary Y axis) in the first case
study
overall aneuploidy, amplifications and deletions across chromosomes 1, 6, 9 and 18 
were plotted against the trends for the scores for the Mad2 and BubRl protein levels 
(Fig. 3.10).
Here, the trends for the average overall aneuploidy (mainly consisting of deletions) 
and for the average amplifications displayed a positive curve, starting in the normal 
ducts and continuing in the ducts with PanIN 2, with the top values seen in PDAC and 
the lymph node metastasis. In contrast, the scores for Mad2 were high in the normal 
ducts, decreased in PanIN 2 and remained stable in PDAC and lymph node metastasis. 
The scores for BubRl followed a mirroring trend, with higher values in one normal 
duct and lesser values for the other histological stages.
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Figure 3.10: The trends for average aneuploidy, average amplifications and average 
deletions (percentages on the primary Y axis) and for the immunostaining scores for 
the Mad2 and BubRl protein levels (values on the secondary Y axis) in the second
case study
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3.4 Discussion
3.4.1 Correlations
Overall, the peak average levels for Mad2 and BubRl were seen in PDAC. However, 
the trend for Mad2 revealed similarly high levels in the normal ducts from PDAC spec­
imens while for the other histological stages the trend appeared random. Meanwhile, 
the levels for BubRl showed a fairly consistent upward trend with low average levels 
in the normal ducts and comparatively high levels in PDAC.
Advanced statistical model analysis revealed correlations between the levels of 
Mad2 and BubRl and aneuploidy but the results need cautious interpretation because 
of the multiple incongruent variables included in the model.
Wu et al. 2004, used the Western Blot method to quantify the levels of Mad2 and 
cyclin B1 and flow cytometry for cell cycle distribution and DNA ploidy in a panel of 
gastric cancers. They found that even though increased levels of Mad2 were found in 
74% of tumours there was no association with the ploidy status or the clinicopatholog- 
ical characteristics of the sample.
3.4.2 BubRl as a potential indicator of aneuploidy
Amplifications are significant molecular events in carcinogenesis and the positive cor­
relation with one of the major checkpoint protein levels reinforces the link between 
the function of the spindle assembly checkpoint and the incidence of chromosomal 
abnormalities (Bharadwaj et al., 2004).
Shin et al. found that BubRl was down regulated in colon adenocarcinomas and 
that the decrease of the BubRl protein levels was potentially linked to chromosomal 
instability in their study (Shin et al., 2003).
Gladhaug et al. used immunohistochemistry on tissue microarrays to investigate 
the levels of spindle checkpoint proteins Aurora A, Mad 2 and BubRl in resected 
adenocarcinomas localized in the head of the pancreas. Their results showed that the 
expression of the mentioned proteins was not associated with ploidy status. Any level 
of BubRl was shown to be sufficient to predict poor prognosis (p=0.006) while Aurora 
A and Mad2 expressions were not related to prognosis. Also, BubRl expression was 
found to independently predict a poor prognosis (Gladhaug IP et al., 2010).
Baker et al. reached the conclusion that increased levels of BubRl are protec­
tive against aneuploidy and potentially extend the healthy lifespan in several tissues 
by correcting mitotic checkpoint impairment and microtubule-kinetochore attachment 
defects. They used transgenic mice to illustrate that sustained high levels of BubRl 
potentially preserve genomic integrity and reduce tumorigenesis (Baker et al., 2013).
In the present study further investigations into potential correlations between the
94
levels of Mad2 and, particularly, BubRl were deemed unsuitable due to sample design 
and limitations in applying suitable statistical tests.
3.4.3 Caveats: low vs high aneuploidy, case studies
The Mad2 and BubRl protein levels failed to show a correlating trend with the levels 
of average aneuploidy in two distinct groups of specimens with PanIN 1 ducts: one 
with relatively low levels of average overall aneuploidy (<39%) and the other with 
relatively high levels of average overall aneuploidy (^39%). This may be related to 
the early premalignant stage or to the fact that in this stage the overall aneuploidy is 
mainly represented by deletions and no significant direct correlation was found with 
the Mad2 and BubRl protein levels.
The case studies represented two specimens with a variety of histological stages 
and thus different levels of overall aneuploidy. They did not reveal any correlations 
between the levels of overall aneuploidy and the levels of the Mad2 and BubRl pro­
teins. This could be related to individual characteristics and heterogeneity of the tu­
mours but also an indication of the complexity of the molecular changes that occur in 
carcinogenesis.
3.4.4 Separate findings
Incidentally, it was noted that the Mad2 and BubRl protein levels in the normal acinar 
cells and islets of Langerhans in the normal pancreatic specimens displayed a similar 
level as the cells in an endocrine tumour (Fig. 3.11 - 3.12). This observation was based 
on seeing the different patterns of Mad2 and BubRl staining and immunostaining of 
a small sample of endocrine tumours following this. The interest comes from the fact 
that endocrine tumours have a much better prognosis than ductal adenocarcinomas. 
The next step would be to compare Mad2 and BubRl levels with tumour size and Ki- 
67 proliferation rate which are the main prognostic factors, and this forms the design 
for a separate research project.
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T u m o u r
Figure 3.11: Immunostaining for BubR 1 levels in the islet endocrine cells in a normal 
pancreatic tissue displays a similar intensity to an endocrine tumour specimen
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Figure 3.12: Immunostaining for Mad2 levels in the islet endocrine cells in a normal 
pancreatic tissue displays a similar intensity to an endocrine tumour specimen
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3.5 Conclusion
The levels of mitotic checkpoint proteins Mad2 and BubRl demonstrated up-regulation 
in the final stage of carcinogenesis but failed to characterize a defined premalignant 
stage where the trend would increase significantly. Limitations related to sample size 
precluded further statistical testing regarding correlations and significance for progress 
and survival. However, the advances in diagnostic and therapeutic methods open the 
field for in depth characterization of the tumorigenesis in pancreatic adenocarcinoma.
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Chapter 4 
General Discussion
Pancreatic carcinogenesis is an intricate process which has been investigated with per­
severance due to the rapid natural progress of the disease. The current pilot study 
aimed to discover links between the aneuploidy levels in progressive premalignant his­
tological stages of PanIN and the characteristics of the respective tumour as well as 
data on the mitotic checkpoint proteins Mad2 and BubRl. We used FISH to score 
the aneuploidy levels displayed by chromosomes 1, 6, 9 and 18 and found that the 
most significant abnormalities were the amplifications and that the overall aneuploidy 
levels increase significantly in the late premalignant stage of PanIN 3 and in ductal 
adenocarcinoma for all the chromosomes analysed. Also, in view of the recognized 
intercorrelations between aneuploidy and anomalies in the mechanisms controlling the 
cell cycle, we proceeded with selecting one group of specimens with relevant levels of 
aneuploidy and subjected them to IHC treatment to see if the levels of expression for 
Mad2 and BubRl reflect a similar pattern to aneuploidy. We found that it was difficult 
to establish a clear correlation, most likely due to the small number of specimens and 
the large panel of variables.
FISH is a widely used method of investigating chromosomal anomalies and the 
extended methods of SKY (spectral karyotyping) and CISH (chromogenic in situ hy­
bridization) allow detailed mapping of specific normal or abnormal DNA sequences, 
in either interphase or metaphase, or global changes in individual chromosomes. For 
the present study, only a snapshot of four chromosomes was included because of time 
limitations and the specimens were scored only by one investigator.
Among other methods used alongside FISH are comparative genomic hybridization 
(CGH), loss of heterogosity (LOH) studies, flow cytometry, microarrays analysis. The 
advantage of these methods is that they are highly specific for genetic mutations which 
allows a detailed mapping of the mutations in a tumour specimen. The disadvantage 
is that they have less specificity for aneuploidy. Using CGH in this study may have 
returned a more detailed profile of the gene mutations corresponding to each of the 
premalignant stage included but less information about the specific aneuploidy levels.
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The aneuploidy levels found in this study were mainly represented by deletions 
which are predominantly related to sectioning bias. Nevertheless, the most relevant 
anomalies were the amplifications which increased significantly in PanIN 3 and ductal 
adenocarcinoma.
Similarly, a study on breast cancer showed that aneuploidy is present in a third of 
cases with atypical hyperplasia, in a larger proportion of intraductal carcinomas and in 
the majority of cases with invasive carcinoma (Shackney S et al., 1995).
In prostate intraepithelial neoplasia, chromosome mis segregation occurs alongside 
point mutations, driving the carcinogenesis to the stage of prostate cancer (Qian J et 
al., 1999).
In Barrett’s oesophagus, most of cell populations are diploid, but in some cases 
aneuploidy arises in one population and it can then spread to a large area, persisting 
for a long period of time before the progression to invasive adenocarcinoma (Reid BJ 
et al., 1996).
A study investigating the potential implications of aneuploidy for improved screen­
ing for colorectal cancer in ulcerative colitis patients found that the evaluation of DNA 
ploidy in correlation to laminin-5 (basement membrane protein) positivity and in­
creased cyclin A expression in aneuploid lesions appeared to be the strongest predictor 
for malignant change in an individual patient (Habermann JK et al., 2012).
Other studies looking at the genetic changes in pancreatic carcinogenesis found that 
the most significant events took place mostly at the PanIN 2 stage (p i6 inactivation, 
MUC1 overexpression) (Koostra JBM et al., 2008, Maitra A et al., 2003). Our study 
found that there was a significant increase in the level of overall aneuploidy and in 
the level of amplifications at the PanIN 3 stage. The levels in the PanIN3 stage were 
similar to the levels found in the ductal adenocarcinoma.
The progress in molecular research in pancreatic carcinogenesis is leading the road 
to individualized genetic therapy. Also, the quest for biomarkers with high specificity 
and sensitivity is a high priority. In this context, aneuploidy could play a role as a 
clinical tool contributing to a panel of biomarkers used to determine the genetic imprint 
of a particular tumour. The standardized methods of scoring aneuploidy are already 
allowing its use in breast cancer to determine the Her2 status which then guides the 
therapy. Likewise, aneuploidy is an indicator of progression in Barrett’s oesophagus, 
uroepithelial tumours and myeloproliferative diseases ( Reid BJ et al., 1996, Qian J et 
al., 1999, Nolte M et al., 1996, Chapman PB et al., 2011).
The large panel of molecular changes in pancreatic carcinogenesis have been in­
vestigated in the hope of discovering more therapeutic targets. Unfortunately, the 
complexity of the molecular changes has imposed limitations on the use of specific 
therapeutic targets.
The most useful molecular change could potentially be a marker easily measurable
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and with an accurate sensitivity and specificity for carcinogenesis.
The abnormal expression of the mitotic checkpoint protein BubRl is linked to ane­
uploidy as one of the mechanisms of chromosomal instability. This protein can be 
easily assessed using immunohistochemistry which is widely available as a standard 
method in the histopathology departments.
Tang Y-C et al. 2011 investigated the potential targeting of aneuploid cells in tu­
mours with specific drugs as part of new cancer therapies. They found that the 17-N- 
allylamino-17-demethoxygeldanamycin (17-AAG), an antibiotic derivative which in­
hibits the heat shock protein 90 (Hsp90) and the 5-Aminoimidazole-4-carboxamide ri­
bonucleotide (AICAR), an analog of adenosine which stimulates the AMP-dependent- 
protein-kinase activity (AMPK), showed increased selectivity against mouse embry­
onic fibroblasts with trisomy. Also, the two mentioned molecules showed some se­
lectivity against cells with chromosomal instability related to specific alterations in 
BubRl and Cdc20. These results were demonstrated also in colorectal cancer cell lines 
and only for AICAR in a subset of lung tumour cell lines, showing that the findings 
are highly specific to certain subsets of tumour cell lines. The potential application, in 
view of the authors, is that once these results would be confirmed by in vivo studies, 
cancer cells could be treated with drugs that increase aneuploidy by impacting on chro­
mosome alignment or the mitotic checkpoint, in sinergy with drugs that act against the 
proteotoxic and energy stress induced by aneuploidy.
The ductal premalignant stages are characterized by progressive cellular changes 
which help differentiate between the different stages. In the early stages there is a pro­
gressive accumulation of mucin while in the late premalignant stages there is desqua­
mation of the cells in the top cellular layer. The macroscopic changes are accompa­
nied by the corresponding molecular changes at every stage. The differences between 
PanIN 1A and IB are often subtle but PanIN IB has more similarities with PanIN 2. 
PanIN 3 can be difficult to differentiate from the adenocarcinoma invading the ducts 
so, in order to ensure a confident grading, the ducts with PanIN 3 need to be away from 
the tumour.
The patients included in the aneuploidy study had a survival period of 12 months, 
on average, ranging between 3 and 18 months. From an observational perspective it 
appeared that a tumour size less than 4 cm was correlated with a better survival while 
a high level of amplifications in the PanIN3 or PDAC areas, with a poorer prognosis. 
However, a robust detailed analysis was not performed due to the small sample size 
and large panel of compounding variables.
No correlation was noted between the Mad2 and BubRl protein levels and survival 
but again the small sample size needs to be taken into account as well as the fact that 
the scoring was limited to histological lesions rather than the entire tumour.
The results from this study need to be considered in the context and limitations of
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the study. The conclusions are not imposing but the small numbers and the limited 
follow-up period are contributing to the limitations. More follow-up, in the form of 
disease-free survival rather than deceased or not type of data would enlarge the pic­
ture about how the aneuploidy in premalignant stages associated with a tumour may 
influence progress and survival.
A recent pilot study found that the progression-free survival period was longer than 
expected in 27% of the selected patients with refractory cancers who were treated using 
targets identified by molecular profiling with IHC, FISH and microarray analysis (Von 
Hof et al., 2010). Prospective clinical trials are currently being designed to include 
a genotypic arm where genetic profiling is the selection criteria in view of validating 
useful novel biomarkers (Schmid RM, 2013).
Future work related to the current study would include extending the period of 
clinical follow-up to allow for better survival analysis, including more specimens with 
PanIN 2 and PanIN 3 lesions which represent a significant step in carcinogenesis, ex­
panding the panel of molecular markers investigated i.e include more chromosomes, 
investigate relevant genetic pathways alongside the numerical anomalies, include a 
larger panel of protein markers. Obtaining specimens of normal pancreatic tissue from 
other centres would expand the negative control group allowing for more in depth 
analysis. Also, pancreatic juice analysis using mass spectrometry would potentially 
demonstrate correlated components linked to carcinogenesis. A separate project is 
planned to investigate the Mad2 and BubRl levels in pancreatic endocrine tumours 
and correlate them with tumour size and Ki-67 proliferation rate which are the main 
prognostic factors. The prognosis for pancreatic endocrine tumours is better than for 
pancreatic adenocarcinoma and the study could reveal what impact the levels of Mad2 
and BubRl have on it.
Chapter 5
Conclusion
Aneuploidy is a significant progressive molecular event in pancreatic carcinogenesis 
and by investigating it alongside other parameters like mitotic checkpoint proteins 
Mad2 and BubRl it could add to the molecular signature of individual tumours.
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